

Multinational attitudes towards AI in healthcare and diagnostics among hospital patients

Subtitle: Cross-sectional evidence from the COMFORT study

Felix Busch¹, MD, Lena Hoffmann², MD, Lina Xu², MD, Longjiang Zhang³, MD PhD, Bin Hu³, MD, Ignacio García-Juárez⁴, MD, Liz N Toapanta-Yanchapaxi⁵, MD, Natalia Gorelik⁶, MD MPH, Valérie Gorelik⁷, Gaston A Rodriguez-Granillo⁸, MD PhD, Carlos Ferrarotti⁹, MD, Nguyen N Cuong¹⁰, MD, Chau AP Thi¹¹, Murat Tuncel¹², MD, Gürsan Kaya¹², MD, Sergio M Solis-Barquero¹³, MSc, Maria C Mendez Avila¹³, MSc, Nevena G Ivanova^{14,15}, PhD, Felipe C Kitamura^{16,17}, MD PhD, Karina YI Hayama¹⁶, MD, Monserrat L Puntunet Bates¹⁸, Pedro Iturralde Torres¹⁹, MD, Esteban Ortiz-Prado²⁰, MD PhD, Juan S Izquierdo-Condoy²⁰, MD, Gilbert M Schwarz²¹, MD, Jochen G Hofstaetter^{22,23}, MD, Michihiro Hide²⁴, MD PhD, Konagi Takeda²⁵, MD, Barbara Perić^{26,27}, MD PhD, Gašper Pilko^{26,27}, MD PhD, Hans O Thulesius^{28,29}, MD PhD, Thomas A Lindow^{30,31}, MD PhD, Israel K Kolawole³², MD, Samuel Adegboyega Olatoke³³, MD, Andrzej Grzybowski³⁴, MD PhD, Alexandru Corlateanu³⁵, PhD, Oana-Simina Iaconi³⁶, MD, Ting Li³⁷, MD PhD, Izabela Domitrz^{38,39}, MD PhD, Katarzyna Kępczyńska^{38,39}, MD, Matúš Mihalčin^{40,41}, PhD, Lenka Fašanková^{40,41}, MD, Tomasz Zatoński⁴², MD, Katarzyna Fułek⁴², MD, András Molnár⁴³, MD PhD, Stefani Maihoub⁴³, MD PhD, Zenewton A da Silva Gama⁴⁴, PhD, Luca Saba⁴⁵, MD PhD, Petros Sountoulides⁴⁶, MD PhD, Marcus R Makowski¹, MD PhD, Hugo JWL Aerts⁴⁷⁻⁴⁹, PhD, Lisa C Adams^{1,#}, MD, Keno K Bresseml^{1,50,#,*}, MD, COMFORT consortium[†]

¹ School of Medicine and Health, Department of Diagnostic and Interventional Radiology, Klinikum rechts der Isar, TUM University Hospital, Technical University of Munich, Munich, Germany

² Department of Radiology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany

³ Department of Radiology, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China

⁴ Department of Gastroenterology and Unit of Liver Transplantation, National Institute of Medical Sciences and Nutrition Salvador Zubirán, Mexico City, Mexico

⁵ Department of Neurology, National Institute of Medical Sciences and Nutrition Salvador Zubirán, Mexico City, Mexico

⁶ Department of Radiology, McGill University Health Center, Montreal, Quebec, Canada

⁷ Dawson College, Montreal, Quebec, Canada

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

⁸ Center for Medical Education and Clinical Research-National Council for Scientific and Technical Research (CEMIC-CONICET), Autonomous City of Buenos Aires, Argentina

⁹ Department of Diagnostic Imaging, Center for Medical Education and Clinical Research "Norberto Quirno" (CEMIC), Autonomous City of Buenos Aires, Argentina

¹⁰ Radiology Center Hanoi, Medical University Hospital Hanoi, Hanoi, Vietnam

¹¹ Hanoi Medical University, Hanoi, Vietnam

¹² Department of Nuclear Medicine, Faculty of Medicine, Hacettepe University, Ankara, Turkey

¹³ Department of Diagnostic and Therapeutic Imaging, Escuela de Tecnologías en Salud, Universidad de Costa Rica, San José, Costa Rica

¹⁴ Departments of Urology and General Medicine, Medical University of Plovdiv, Plovdiv, Bulgaria

¹⁵ St. Karidad MHAT, Karidad Medical Health Center, Cardiology, Plovdiv, Bulgaria

¹⁶ Department of Radiology, Universidade Federal de São Paulo, São Paulo, Brazil

¹⁷ Diagnósticos da América SA (DASA), São Paulo, Brazil

¹⁸ Unidad de Calidad, National Institute of Cardiology Ignacio Chávez, Mexico City, Mexico

¹⁹ Subdirection of Diagnosis and Treatment, National Institute of Cardiology Ignacio Chávez, Mexico City, Mexico

²⁰ One Health Research Group, Faculty of Health Science, Universidad de Las Américas, Quito, Ecuador

²¹ Department of Orthopaedics and Trauma Surgery, Medical University of Vienna, Vienna, Austria

²² Michael Ogon Laboratory for Orthopaedic Research, Hospital Vienna-Speising, Vienna, Austria

²³ 2nd Department, Orthopaedic Hospital Vienna-Speising, Vienna, Austria

²⁴ Department of Dermatology, Hiroshima Citizens Hospital, Hiroshima, Japan

²⁵ Department of Radiology, Hiroshima Citizens Hospital, Hiroshima, Japan

²⁶ Department of Surgical Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia

²⁷ Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia

²⁸ Research and Development Department Region Kronoberg, Växjö, Sweden

²⁹ Department of Medicine and Optometry, Linnaeus University, Kalmar, Sweden

³⁰ Department of Clinical Physiology, Research and Development, Växjö Central Hospital, Växjö, Sweden

³¹ Department of Clinical Physiology, Clinical Sciences, Lund University, Lund, Sweden

³² Department of Anesthesia, University of Ilorin/Teaching Hospital, Ilorin, Nigeria

³³ Department of Surgery, University of Ilorin/Teaching Hospital, Ilorin, Nigeria

³⁴ Institute for Research in Ophthalmology, Foundation for Ophthalmology Development, Poznań, Poland

³⁵ Department of Respiratory Medicine and Allergology, Nicolae Testemițanu State University of Medicine and Pharmacy, Chișinău, Republic of Moldova

³⁶ Research Cooperation Unit within the Research Department, National Institute of Research in Medicine and Health, Nicolae Testemițanu State University of Medicine and Pharmacy, Chișinău, Republic of Moldova

³⁷ Department of Rheumatology, Shanghai Jiao Tong University School of Medicine, Renji Hospital, Shanghai, China

³⁸ Department of Neurology, Faculty of Medicine and Dentistry, Medical University of Warsaw, Warsaw, Poland

³⁹ Department of Neurology, Bielanski Hospital, Warsaw, Poland

⁴⁰ Department of Infectious Diseases, Faculty of Medicine, Masaryk University, Brno, Czech Republic

⁴¹ Department of Infectious Diseases, University Hospital Brno, Brno, Czech Republic

⁴² Department of the Otolaryngology, Head and Neck Surgery, Wrocław Medical University, Wrocław, Poland

⁴³ Department of Otorhinolaryngology, Head and Neck Surgery, Semmelweis University, Budapest, Hungary

⁴⁴ Department of Collective Health, Federal University of Rio Grande do Norte, Natal, Brazil

⁴⁵ Department of Radiology, Azienda Ospedaliero Universitaria (A.O.U.), di Cagliari - Polo di Monserrato s.s. 554 Monserrato, Cagliari, Italy

⁴⁶ Department of Urology, Aristotle University of Thessaloniki, Thessaloniki, Greece

⁴⁷ Artificial Intelligence in Medicine (AIM) Program, Mass General Brigham, Harvard Medical School, Boston, MA, USA

⁴⁸ Departments of Radiation Oncology and Radiology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA, USA

⁴⁹ Radiology and Nuclear Medicine, CARIM & GROW, Maastricht University, Maastricht, The Netherlands

⁵⁰ School of Medicine and Health, Institute for Cardiovascular Radiology and Nuclear Medicine, German Heart Center Munich, TUM University Hospital, Technical University of Munich, Munich, Germany

* Correspondence to: Dr Keno K Bressemer, MD; Address: School of Medicine and Health, Institute for Cardiovascular Radiology and Nuclear Medicine, German Heart Center Munich, TUM University Hospital, Technical University of Munich, Lazarettstraße 36, 80636 Munich, Germany; Telephone number: +49-89 1218 4511; E-mail: keno.bressemer@tum.de

These authors contributed equally to this work.

† COMFORT consortium members are listed at the end of the manuscript.

Abstract

The successful implementation of artificial intelligence (AI) in healthcare is dependent upon the acceptance of this technology by key stakeholders, particularly patients, who are the primary beneficiaries of AI-driven outcomes. This international, multicenter, cross-sectional study assessed the attitudes of hospital patients towards AI in healthcare across 43 countries. A total of 13806 patients at 74 hospitals were surveyed between February and November 2023, with 64.8% from the Global North and 35.2% from the Global South. The findings indicate a predominantly favorable general view of AI in healthcare, with 57.6% of respondents expressing a positive attitude. However, attitudes exhibited notable variation based on demographic characteristics, health status, and technological literacy. Female respondents and those with poorer health status exhibited fewer positive attitudes towards AI use in medicine. Conversely, higher levels of AI knowledge and frequent use of technology devices were associated with more positive attitudes. It is noteworthy that less than half of the participants expressed positive attitudes regarding all items pertaining to trust in AI. The lowest level of trust was observed for the accuracy of AI in providing information regarding treatment responses. Patients exhibited a strong preference for explainable AI and physician-led decision-making, even if it meant slightly compromised accuracy. This large-scale, multinational study provides a comprehensive perspective on patient attitudes towards AI in healthcare across six continents. Findings suggest a need for tailored AI implementation strategies that consider patient demographics, health status, and preferences for explainable AI and physician oversight. All study data has been made publicly available to encourage replication and further investigation.

Introduction

Artificial Intelligence (AI) has become increasingly prevalent in various industries and public sectors, including healthcare.^{1,2} In particular, the development of large language models (LLMs) such as ChatGPT has intensified public discourse on the potential impact of AI, especially in healthcare.³⁻⁵

AI technologies offer promising solutions to pressing healthcare challenges, including staff shortages, high administrative costs, and economic constraints.⁶ In clinical practice, AI applications range from assisting with image-based diagnoses to personalizing treatment strategies and predicting risk factors and therapy responses.⁷⁻⁹ Beyond direct patient care, AI facilitates drug discovery and development while streamlining administrative tasks such as data extraction, curation, and report structuring.^{10,11}

The economic implications are substantial, with projections suggesting that AI technologies could reduce healthcare spending in the United States by five to ten percent, potentially yielding annual savings of \$200 to \$360 billion.¹² The rapid integration of AI in healthcare is further evidenced by the Food and Drug Administration's approval of 692 AI- and machine learning-enabled medical devices through July 2023, with 478 (69.1%) approved in just the past three years.¹³

Despite this rapid growth, the benefits of AI applications to patient care are not always clear.¹⁴ While patient acceptance is important for the sustainable adoption of AI, patients may not always have the opportunity to consent to its use.^{15,16} To address this challenge, adopting biopsychosocial perspectives that recognize patients' unique experiences, beliefs, and values in health maintenance can help steer AI towards patient-centered care.¹⁵⁻²¹ Moreover, fostering patient trust in AI is vital, as it may positively influence adherence to AI-assisted care and related health outcomes, as demonstrated in conditions such as diabetes management.^{22,23}

Exploring patient perspectives can, therefore, be highly beneficial in ensuring the successful integration of AI in healthcare. Patients whose health is directly affected by AI – either through improved treatment and diagnosis or by potential consequences of immature AI – may hold views that diverge significantly from those of clinicians.

However, a notable knowledge gap exists regarding patient attitudes, particularly on a large, international scale. Existing studies are limited to data from one or at most two countries, failing to capture the likely variations in patient attitudes across different sociodemographic contexts.²⁴⁻³¹

To address these challenges, we conducted the first large-scale, international, multicenter survey of hospital patients to determine 1) patients' trust, concerns, and preferences towards AI in healthcare and diagnostics and 2) factors that influence patient attitudes. By focusing on the voices of patients from diverse global contexts, including from the Global North and South, this study aims to provide a comprehensive, global perspective on patient attitudes towards AI in healthcare, thereby contributing to the development of patient-centered AI applications.

Methods

Study Design

This multicenter, international, cross-sectional study was conducted in accordance with the Strengthening the Reporting of Observational studies in Epidemiology (STROBE) statement (see eTable 13) and American Association for Public Opinion Research best practices for survey research. Ethical approval was obtained from the Charité – Universitätsmedizin Berlin (EA4/213/22), which served as the lead institution, and from all other participating hospitals according to their institutional policies (see eTable 14). Given the unsupervised and anonymous design of the instrument, informed consent was waived to preserve participant anonymity.

Setting and Participants

The survey was administered to a non-probability convenience sample at 74 COMFORT network hospitals across 43 countries. Local staff disseminated the surveys, which were also displayed in prominent areas such as waiting rooms, from February 1, 2023, to November 1, 2023. We targeted radiology departments as the primary site for the survey because of the high turnover of patients with a wide range of conditions. Participants could submit their responses through drop boxes or directly to staff. Collected data from all participating sites were then centrally analyzed at Charité Berlin. The sample size was determined using Cochran's formula. Assuming a 50% response distribution (which was chosen because it allows for the most conservative estimate), a 95% confidence level, and a five percent margin of error, we determined a minimum sample size of 385 respondents. Inclusion criteria were patients aged 18 years or older who attended a participating department during the study period, agreed to participate in the survey voluntarily, and were able to complete the questionnaire independently in one of 26 local languages (Azerbaijani, Bahasa Indonesia, Bulgarian, Croatian, Czech, Dutch, English, French, German, Greek, Hindi, Hungarian, Italian, Japanese, Macedonian, Malayalam, Mandarin, Polish, Portuguese, Romanian, Slovenian, Spanish, Swedish, Thai, Turkish, Vietnamese). Patients who did not complete any items or only items capturing variables for sample stratification were excluded.

Survey Development and Design

To inform the survey construct for our measures on patient attitudes towards the use of AI in healthcare and diagnostics, we followed the systematic review by Young et al., synthesizing 23 qualitative, quantitative, or mixed-method original articles on patient and public attitudes toward clinical AI.²⁴ In addition, a sample of ten voluntary patients who visited the Department of Radiology at Charité – Universitätsmedizin Berlin in January 2023 were interviewed to explore how patients understand and conceptualize the construct, starting with an unprompted discussion followed by focused questions on our measures. Based on the systematic review and semi-structured interviews, a multidisciplinary expert panel from the COMFORT consortium, including patient representatives,

radiologists, urologists, medical faculty members and educators, AI researchers and developers, and biomedical ethicists and statisticians from seven countries, developed a 26-item survey. The comprehensibility and overall length of our instrument were evaluated in cognitive interviews with ten patients at the Department of Radiology, Charité Berlin, followed by a pilot study to test the internal reliability, consistency, and unidimensionality.

The pilot study group consisted of 100 patients visiting the Department of Radiology, Charité – University Medicine Berlin in January 2023. Psychometric validation of the questionnaire was performed using "R" version 4.2.2, including the packages "tidyverse" (1.3.2), "lavaan" (0.6-13), and "psych" (2.2.9).³²⁻³⁴ Baseline characteristics of the pilot study group are displayed in eTable 15.

The internal consistency of the questionnaire was assessed using Cronbach's alpha. The following scales with six items each were evaluated: "Trust in AI," "AI and Diagnosis," and "Preferences and Concerns Towards AI." The "Trust in AI" scale demonstrated excellent internal consistency ($\alpha = .94$), while the "AI and Diagnosis" and "Preferences and Concerns Towards AI" scales showed good consistency ($\alpha = .80$ and $\alpha = .86$, respectively).

The Kaiser-Meyer-Olkin (KMO) measure and Bartlett's test of sphericity further validated the appropriateness of the data for factor analysis. The KMO measure was .93, indicating that sampling was adequate and the data were suitable for factor analysis. Bartlett's Test of Sphericity yielded a significant result ($P < .001$), confirming that the variables were sufficiently correlated for factor analysis. Confirmatory factor analysis was used to assess the construct validity of the questionnaire. Model fit indices indicated a reasonable fit to the data, with a Comparative Fit Index of 0.956 and a Tucker-Lewis Index of 0.949, both above the recommended threshold of 0.9. The Root Mean Square Error of Approximation was .066, and the Standardized Root Mean Square Residual was .055, indicating a good model fit. Factor loadings were significant, indicating strong relationships between items and their respective latent constructs.

Variables

The instrument consisted of three dimensions: "Trust in AI," "AI and Diagnosis," and "Preferences and Concerns Towards AI," each with six items, complemented by a general data section with eight items (self-reported gender, age, highest educational level, weekly use of technological devices, health status, AI knowledge, and general attitudes towards AI in medicine and healthcare). We have chosen to collect data on gender rather than sex to allow for a more inclusive data collection that recognizes diverse individuals and reflects social identities, roles, and experiences that are not captured by biological characteristics.

"Trust in AI" measured confidence in AI improving healthcare, trust in AI providing information about health, diagnosis, response to treatment and making vital decisions, and agreement with the use of AI depending on disease severity using four- and five-point Likert scale items. "AI and Diagnosis" assessed attitudes towards AI

analyzing X-rays and cancer, its role as a second opinion for physicians, trade-offs in diagnostic accuracy, and diagnostic preferences if AI and physicians would have equal accuracy using four- and five-point Likert scale and two multinomial items. "Preferences and Concerns Towards AI" assessed attitudes on the use of AI in healthcare facilities, preference for visiting such facilities, and concerns about the impact of AI on cost, data security, physician-patient interaction, and replacement of human physicians using four- and five-point Likert scale items.

Statistical Analysis

Statistical analyses were conducted using 'R' version 4.3.1, employing the packages 'tidyverse' (2.0.0), 'ordinal' (2023.12-4), and 'lme4' (1.1-35-1) for data manipulation and modeling.^{32,35,36} Survey results were summarized using frequencies and percentages for the total cohort, the Global North and Global South based on the definitions of the United Nations Finance Center for South-South Cooperation, and by continent according to the location of the hospital visited using the United Nations Geoscheme.^{37,38} To assess differences between patient groups (categorized by gender, age, highest educational level, number of technical devices used weekly, AI knowledge, and health status), we employed cumulative link mixed models (CLMMs) and binary mixed-effects models. CLMMs were used for ordinal response items to account for the ordered nature of the responses while considering both the grouping factors as fixed effects and the collection site as a random effect to control for site-specific clustering. For questions with categorical outcomes, binomial logistic regression models were fitted, utilizing a one-vs-rest strategy. Cases with missing data were excluded from the respective analyses. Adjusted *P* values were calculated using a Bonferroni correction to address the issue of multiple comparisons. An adjusted *P* value of <.05 was considered statistically significant.

Data Availability Statement

The full dataset and data dictionary are publicly available under CC-BY 4.0 international license at figshare: <https://doi.org/10.6084/m9.figshare.24964488>

Code Availability Statement

The code for all statistical analyses is publicly available at: <https://github.com/kbressemer/ai-survey>

Ethics and Inclusion Statement

This study focused on capturing and comparing a wide range of hospital patient attitudes towards AI worldwide, using a non-probability convenience sample of patients from network hospitals of the COMFORT project, funded by the European Union's Horizon Europe program and led by Charité Berlin. Each site obtained Institutional Review Board approval to conduct the survey at their institution in accordance with local guidelines. At least one principal investigator from each site was involved in the design and implementation of the survey, including substantial contributions to survey development, planning, translation (if applicable), data collection,

interpretation, and validation of results. The questionnaires were completely anonymous. If participants added personal identifiers, such as names and contact information, these questionnaires were discarded to prevent the identification of individuals. In addition, all sites agreed that the original questionnaires would never be published or shared with unauthorized individuals or organizations. All participating sites had full access to the survey data and agreed that the aggregated electronic results would be made publicly available under the international CC-BY 4.0 license with publication. All consortium members have critically reviewed the manuscript, agreed to the final version for publication, and take responsibility for the accuracy and integrity of the work. Where available, we have discussed local and regional research relevant to our findings, although, at the time of manuscript preparation, all previous studies capturing patient attitudes towards AI were based in the Global North or China.²⁴⁻³¹

Results

Participants

A total of 13955 surveys were collected, of which 1.1% (n=149/13955) were excluded from analysis due to no response to any item (0.1%, n=12/13955) or only to items in the general data section (1%, n=137/13955); see characteristics of excluded patients in eTable 1. Of the 13806 patients included, most surveys were collected in radiology departments (51.3%, n=7081/13806), followed by gastroenterology (7.9%, n=1098/13806), cardiology (5.4%, n=743/13806), and 21 other specialty departments (35.4%, n=4884/13806). Most patients (64.8%, n=8951/13806) visited hospitals in the Global North. Europe accounted for 41.7% (n=5764/13806) of patients, followed by Asia (25.2%, n=3473/13806), North America (16.5%, n=2284/13806), South America (9.7%, n=1336/13806), Africa (5.3%, n=728/13806), and Oceania (1.6%, n=221/13806). Figure 1 illustrates the geographical distribution of participating institutions. A detailed list of participating institutions and corresponding departments and patient numbers can be found in eTable 2.

Sociodemographic profiles and technology literacy, health status, and AI knowledge are shown in Table 1 for the overall study population and the region-specific subgroups. Gantt diagrams depicting the responses for each survey item for the total study cohort can be viewed in Figure 2. Regional breakdowns for each item response are presented in Table 2.

General attitudes towards AI

Most patients were positive about the general use of AI in medicine (question (Q) 1; 57.6%, n=7775/13502) and favored its increasing application in healthcare (Q2; 63%, n=8381/13314). Female respondents tended to be slightly less positive about the general use of AI in medicine than males, with 55.6% (n=3511/6318) having "rather positive" or "extremely positive" views on AI compared to 59.1% (n=4057/6864) of males (Q1; adjusted odds

ratio (AOR): 0.84, 95% confidence interval (CI): 0.78 to 0.9; see eTables 3 and 8). Patients tended to be more dismissive towards AI if they reported worse overall health status. Of the patients with very poor health status, 26.3% (n=53/199) had "extremely negative" and 29.2% (n=58/199) "rather negative" views on AI. In comparison, only 1.3% (n=33/2538) and 5.3% (n=134/2538) of patients with very good health shared those views (see eTable 9). This trend was also reflected in the AOR, which increased with higher self-reported health status, ranging from 0.15 (95% CI: 0.11 to 0.21) for very poor to 0.71 (95% CI: 0.64 to 0.78) for good, compared with those who indicated very good health (Q1; see eTable 4).

Similar observations were made for higher AI knowledge, where 83.3% (n=175/210) of self-reported AI experts had "rather positive" or "extremely positive" views, compared to 38% (n=667/1755) of those with no AI knowledge (Q1; see eTable 10). For this question, AORs ranged from 1.75 (95% CI: 1.56 to 1.96) for little knowledge to 7.11 (95% CI: 5.19 to 9.74) for expert compared to no knowledge (Q1; see eTable 5).

Patients with a higher technological affinity or literacy, measured by the number of technology devices used weekly, also showed a higher tendency to express positive views on AI (Q1; AOR: 1.17, 95% CI: 1.13 to 1.21; see eTable 6). Age and level of education did not significantly influence general attitudes (Q1/Q2; see eTables 6 and 7). Absolute survey results for each item stratified by gender, education level, health status, AI knowledge, age, and weekly use of technological devices are presented in eTables 8-12.

Trust in AI

Less than half of the respondents indicated a positive attitude towards the items related to trust in AI. Overall, 48.5% (n=6573/13542) of patients surveyed were confident that AI would improve healthcare (Q3), 43.9% (n=5935/13507) trusted AI to provide reliable health information (Q4), 43.6% (n=5887/13496) trusted AI to provide accurate information about their diagnosis (Q5), and 41.8% (n=5637/13480) trusted AI to provide accurate information about their response to therapy (Q6).

While the majority of female patients responded positively towards AI for all items on trust, they were slightly less favorable than male patients, reflected in the lower AORs compared to males, ranging from 0.76 (Q5 and Q6; 95% CIs: 0.71 to 0.8 and 0.71 to 0.81) to 0.8 (Q4; 95% CIs: 0.74 to 0.85; see eTable 3). For instance, in Q3, 45% (n=2862/6357) of female respondents had "much" or "very much" confidence that AI can improve healthcare, compared to 51.4% (n=3526/6861) of male respondents (see eTable 8).

For Q3 to Q6, patients with expert knowledge consistently expressed higher tendencies to answer more favorably towards AI with AORs ranging from 3.26 (Q4; 95% CI: 2.41 to 4.41) to 5.11 (Q3; 95% CI: 3.76 to 6.94; see eTable 5). For example, in Q3, 77.3% (n=163/211) of self-reported AI experts had "much" or "very much" confidence in AI improving healthcare, compared to only 35.9% (n=630/1756) of those with no AI knowledge (see eTable 10).

Similarly, AORs for Q3 to Q6 increased with better self-reported health status, with the reference group of patients reporting very good health consistently demonstrating the highest AORs (see eTable 4).

Only 11.4% (n=1499/13139) of patients were against using AI regardless of the disease (Q7). In contrast, 27.9% (n=3661/13139) preferred to use AI only for minor conditions such as the common cold, 26.7% (n=3510/13139) accepted AI for moderate conditions such as appendicitis, and 34% (n=4469/13139) were open to using AI for severe conditions such as traffic accidents. Notably, 42.9% (n=5758/13437) of patients trusted a highly accurate AI to make vital health decisions on their behalf (Q8). However, this trust varied significantly in terms of both health status and AI knowledge. 50.4% (n=1273/2526) of patients with very good health trusted AI for vital decisions, compared to only 26% (n=51/196) of those with very poor health, reflected in an AOR of 0.45 (95% CI: 0.33-0.62; see eTables 4 and 9). 91.4% (n=192/210) of self-reported AI experts trusted or strongly trusted AI for vital decisions, compared to only 36% (n=628/1745) of those with no AI knowledge, with AORs ranging from 1.18 (95% CI: 1.06-1.32) for little knowledge to 2.06 (95% CI: 1.52-2.8) for expert knowledge (see eTables 5 and 10).

Preferences towards AI applications in diagnostics and healthcare facilities

The majority of patients preferred healthcare facilities that use AI software to assist in diagnosis (Q15), with 62% (n=7841/12652) expressing a positive attitude. Similarly, most patients indicated that they would often or always prefer facilities that use AI (Q16; 71.4%, n=8922/12497). Female patients tended to be less positive than males for both items (Q15: 59.9% (n=3585/5990) versus 63.9% (n=4041/6329); Q16: 68.7% (n=4061/5912) versus 73.7% (n=4618/6263)) with AORs of 0.79 (95% CI: 0.78 to 0.79) for Q15 and 0.81 (95% CI: 0.75 to 0.88) for Q16 (see eTables 3 and 8). AI knowledge also significantly influenced these preferences, with AORs for expert knowledge of 4.77 (95% CI: 3.51 to 6.48) for Q15 and 3.18 (95% CI: 2.29 to 4.42) for Q16, compared to no knowledge. For instance, 79.7% (n=161/202) of self-reported AI experts had positive attitudes towards healthcare facilities using AI compared to 46.2% (n=747/1616) of those with no knowledge (Q15; see eTables 5 and 9).

Younger age and higher technological literacy were only associated with a more positive attitude for Q15 (see eTable 6).

The use of AI was viewed positively in various medical scenarios: 59.3% (n=7697/12986) supported the use of AI for X-ray analysis (Q9), 54.6% (n=7073/12953) for cancer diagnosis (Q10), and 68% (n=8804/12961) for availability as a second opinion for physicians (Q11). Notably, 70.2% (n=8816/12563) of patients preferred explainable AI (Q12), even if this meant a trade-off in accuracy compared to black-box models. This observation was consistent across subgroups with small and mostly non-significant differences.

Regarding diagnostic accuracy (Q13), 46.5% (n=5701/12268) preferred AI with higher sensitivity compared to 36.3% (n=4452/12268) who preferred AI with higher specificity. When asked about joint diagnosis by physicians and AI when both have the same accuracy (Q14), the majority (72.9%, n=9222/12652) preferred a collaborative diagnostic approach where physicians make the final decision. Only a small proportion (4.4%, n=562/12652) supported the idea of fully autonomous AI in diagnosis, while 6.6% (n=829/12652) favored physicians making the diagnosis independently of AI.

Concerns towards AI

Concerns about data protection were expressed by 53.2% (n=6737/12668) of patients (Q17). Even more participants were concerned about AI's potential impact on healthcare delivery: 61.8% (n=7823/12669) feared that AI could reduce doctor-patient interaction (Q18), while 61.7% (n=7886/12773) were concerned that AI could replace human doctors (Q19). The expectation that AI will lead to increased healthcare costs was a concern for 57.4% (n=7319/12751) of patients (Q20).

Younger age was associated with lower concerns for all items (Q17 to Q20; AORs, 95% CIs ranging from 0.36, 0.29 to 0.46 (Q18) to 0.62, 0.49 to 0.79 (Q17); see eTable 6). However, absolute differences were small, with 53.3% of patients ≤ 48 years (n=3167/5938) vs. 53.4% (n=2984/5593) of patients > 48 years expressing concerns in Q17 or 57.4% (n=3412/5940) of patients ≤ 48 years vs. 66.7% (n=3731/5592) of patients > 48 years expressing concerns in Q18 (eTable 11).

Notably, higher self-reported AI knowledge was associated with lower concerns about the replacement of human doctors (Q19; 50.2% (n=107/205) of experts vs. 62.2% (n=1037/1668) with no knowledge, AOR expert: 1.84, 95% CI: 1.35 to 2.5) and increased healthcare costs (Q20; 51.7% of experts versus 62.6% with no knowledge, AOR expert: 1.83, 95% CI: 1.34 to 2.5; see eTables 5 and 10).

Discussion

This multinational study represents the most extensive and comprehensive survey to date of patient attitudes toward AI in healthcare worldwide. With 13806 participants from 43 countries, our findings provide a multifaceted understanding of patients' preferences, trust, and concerns about AI in healthcare. The results illustrate a nuanced landscape of attitudes, with most patients expressing support for the use of AI in healthcare while also articulating concerns about its implementation.

Previous studies examining patient attitudes towards AI in healthcare have been limited to individual countries or specific clinical areas. For example, positive attitudes towards the use of AI in healthcare ranged from 53% in a German tertiary referral hospital to 94% in a German radiology patient study.^{26,29,31,39} Although this overall trend

is also reflected in our findings, with 57.6% of respondents expressing a generally positive view of the use of AI in healthcare, our study provides a more comprehensive and granular understanding of patient attitudes. Notably, 71.4% of patients indicated a preference for healthcare facilities that utilize AI software (Q16). Interestingly, the preference for facilities utilizing AI was higher than the percentage of patients expressing a generally positive view of AI (57.6%, Q1) or favoring an increase in AI use in healthcare (63%, Q2). One potential explanation for this discrepancy is that the use of AI is perceived as a marker of modern technology, and patients anticipate that other aspects of the hospital may also be more modern. This perception may provide a rationale for healthcare providers to allocate greater resources toward AI solutions, particularly in contexts where the private healthcare sector is prominent.

Our study also uniquely demonstrates how attitudes towards AI vary significantly based on demographic factors and health status. Young, healthy males tend to view AI most positively, while older patients and those with poorer health express more reservations. This gradient of acceptance suggests that as the likelihood of AI being applied to one's own care increases, patients become more cautious in their outlook. Similar trends were also observed for the use of AI depending on disease severity, where patients were less likely to accept AI for more severe conditions. This finding is also supported by a recent study by Khullar et al., who found that 31% of respondents to an online survey agreed with the use of AI in cancer diagnosis, compared to 55% for chest X-rays.²⁹ However, it is important to note that their study allowed respondents to agree with AI use in multiple scenarios and focused on AI potentially replacing doctors in these activities. In contrast, our study examined the acceptance of AI application across a spectrum of disease severities, regardless of whether it was supplementing or replacing human doctors. In contrast, a study by Robertson et al. involving 2675 patients showed no significant preference for AI use based on disease severity.²⁵

A noteworthy finding of our study is the pronounced inclination towards explainable AI, which was observed to be independent of demographic characteristics. Approximately 70% of patients indicated a preference for AI with transparent decision-making processes, even if this entailed a slight compromise in accuracy. This preference for explainability is considerably higher than that reported in a previous US study, which found that only 42% of patients felt uncomfortable with highly accurate AI diagnoses that lacked explainability.²⁹ Our study demonstrates a global desire for transparency in AI-driven healthcare decisions, which has significant implications for the development and implementation of AI in medical settings.

Moreover, our results reinforce the importance of maintaining human oversight in AI-assisted healthcare. Despite the ongoing debate about the use of autonomous AI in healthcare,⁴⁰⁻⁴² our findings indicate that the majority of patients prefer physicians to retain control when utilizing AI in clinical settings. Notably, only 4% of patients

preferred fully autonomous AI. Supporting these findings, previous studies have reported that 67% to 96% of patients would prefer physician-led diagnoses to AI recommendations.^{26,31,43,44} On the other hand, the preference for physicians to make diagnoses without the assistance of AI was expressed by only 6.6% of patients, suggesting a substantial endorsement of AI among the survey participants.

Despite the generally favorable views on AI, we also observed multiple concerns among respondents. Over half voiced apprehensions about data security, reduced doctor-patient interaction, and potential increases in healthcare costs. These findings underscore the need for a balanced approach to AI implementation in healthcare, one that addresses patient concerns while leveraging the potential benefits of AI technology.

This study has limitations. The non-probability convenience sampling likely resulted in low response rates and may have introduced selection and noncoverage bias, affecting data representativeness. Despite these issues, the sampling method enabled the collection of diverse patient attitudes across various countries and healthcare settings. The uncertain selection probabilities and unsupervised survey administration may limit the robustness of inferences. To address site-specific clustering and stratification variations, we used mixed models for subgroup analysis. While not fully generalizable to all hospital populations, the findings offer valuable insights into multinational patient attitudes towards AI in healthcare and can inform future research. The authors encourage replication and extension, particularly in underrepresented populations, and have made study materials available to support this.

In conclusion, this global survey, which includes patients across six continents, provides the most comprehensive snapshot of patient attitudes toward AI in healthcare to date. Our findings reveal a nuanced landscape. While patients generally favor AI-equipped healthcare facilities and recognize AI's potential, they strongly prefer explainable AI systems and physician-led decision-making. Furthermore, attitudes vary significantly based on demographics and health status. These insights underscore the critical need for healthcare providers and AI developers to prioritize transparency, maintain human oversight, and tailor AI implementation to patient characteristics.

Acknowledgments

The authors thank: at the College of Pharmacy and Health Sciences, Ajman University, United Arab Emirates, Ms Dania S Rammal, Ms Aya Mutasem Baradie, and Ms Farrah E Elsubeihi for supporting the data collection; at the Department of Medical Oncology, Dr BRA Institute Rotary Cancer Hospital, Ms Ritika Arora (supporting the data collection), Ms Swetambri Sharma (supporting the translation), Ms Mamta Kumari (supporting the translation), Ms Ayushi Bansal (supporting the translation), and Ms Vasudha V (supporting the translation) for supporting the data collection and questionnaire translation into Hindi; at the Diagnostic and Imaging Services Department, SSD Infectious Diseases 3 - Ultrasound, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, Ms Nadia Locatelli for supporting the data collection; at the Department of Radiology, Alfred Health, Melbourne, Victoria, Australia, Mr Dominic Buensalido and Ms Christina Tasiopoulos for supporting the data collection and Mr Adil Zia for supporting the ethics submission and data collection; at the Department of Radiology, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China, Mr Jian Zhong for supporting the data collection; at the Department of Gastroenterology, Lakeshore Hospital, Kochi, India, Mr Binimol Shaji for supporting the data collection; at the Department of Radiology, Ramón y Cajal University Hospital, Madrid, Spain, Dr Ana M Ayala Carbonero and Dr María J Carrillo Guivernau for supporting the data collection; at the Department of Imaging, A.C.Camargo Cancer Center, São Paulo, Brazil, Dr Paula NVP Barbosa for supporting the data collection; at the Department of Radiology, Kantonsspital Glarus, Glarus, Switzerland, Mr Christian Weiser for supporting the data collection; all hospital and administration staff at each location who made this study possible. This research is funded by the European Union (COMFORT (Computational Models FOR patient stratification in urologic cancers – Creating robust and trustworthy multimodal AI for health care), project number: 101079894, authors involved: Petros Sountoulides, Renato Cuocolo, Virginia Dignum, Guillermo de Velasco, Alessa Hering, Lili Jiang, George Kolostoumpis, Alexander Loeser, principal investigator: Keno K Bressemer, sponsors' website: <https://www.comfort-ai.eu>). Views and opinions expressed are, however, those of the authors only and do not necessarily reflect those of the European Union. The European Union cannot be held responsible for them. The funding had no role in the study design, data collection and analysis, manuscript preparation, or decision to publish.

Author Contributions

Conceptualization: Felix Busch, Lena Hoffmann, Lina Xu, Zenewton A da Silva Gama, Petros Sountoulides, Lisa C Adams, Keno K Bressemer, Renato Cuocolo, Virginia Dignum, Guillermo de Velasco, Alessa Hering, Lili Jiang, George Kolostoumpis, Alexander Loeser, Marcus R Makowski, Daniel Truhn; Project administration: Felix Busch, Lena Hoffmann, Lisa C Adams, Keno K Bressemer; Resources: All COMFORT consortium members; Software: Felix Busch, Lena Hoffmann, Lisa C Adams, Keno K Bressemer; Data curation: Felix Busch, Lena Hoffmann, Lisa C Adams, Keno K Bressemer; Formal analysis: Felix Busch, Lena Hoffmann, Lisa C Adams, Keno K Bressemer; Funding acquisition: Felix Busch, Lena Hoffmann, Lina Xu, Petros Sountoulides, Lisa C Adams, Keno K Bressemer, Renato Cuocolo, Virginia Dignum, Guillermo de Velasco, Alessa Hering, Lili Jiang, George Kolostoumpis, Alexander Loeser, Marcus R Makowski; Investigation: All COMFORT consortium members; Methodology: Felix Busch, Lena Hoffmann, Lisa C Adams, Keno K Bressemer; Supervision: Felix Busch, Lisa C Adams, Keno K Bressemer; Validation: All COMFORT consortium members; Visualization: Felix Busch, Esteban Ortiz-Prado, Keno K Bressemer; Writing – original draft preparation: Felix Busch, Lisa C Adams, Keno K Bressemer; Writing – review & editing: All COMFORT consortium members.

Table of COMFORT consortium members (ordered alphabetically by surname).

Full name	Affiliation	E-mail	ORCID
Álvaro Aceña Navarro	Department of Cardiology, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain; Department of Medicine, Universidad Autónoma de Madrid, Madrid, Spain	aacena@fjd.es	0000-0002-5975-5761
Catarina Águas	Department of Radiology, Algarve University Hospital Center, Faro, Portugal	acaguas@chua.min-saude.pt	0000-0002-1575-6367
Martina Aineseder	Department of Radiology, Hospital Italiano de Buenos Aires, Autonomous City of Buenos Aires, Argentina	martina.aineseder@hospitalitaliano.org.ar	0000-0002-8733-856X
Muaed Alomar	Department of Clinical Sciences, College of Pharmacy and Health Sciences, Ajman University, Ajman, United Arab Emirates	muayyad74@yahoo.com	0000-0001-6526-2253
Rashid Al Sliman	Department of Urology, Faculty of Health Sciences Brandenburg, Brandenburg Medical School Theodor Fontane, Brandenburg a.d. Havel, Germany	rashid.al-sliman@uk-brandenburg.de	0009-0008-6422-3402
Gautam Anand	Department of Oncosurgery, Max Institute of Cancer Care, Vaishali, Delhi, India	gautam16alok@gmail.com	-
Salita Angkurawaranon	Department of Radiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand	salita.ang@cmu.ac.th	0000-0001-6211-5717
Shuheï Aoki	Department of Cardiovascular Medicine, Chiba University, Graduate School of Medicine, Chiba, Japan	ariesdiamond.04@gmail.com	-
Samuel Arkoh	Department of Radiology, Wenchi Methodist Hospital, Wenchi, Ghana	sampapaarkoh1997@gmail.com	0000-0003-3853-5898
Gizem Ashraf	Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne, Victoria, Australia	gizem.ashraf@gmail.com	0000-0003-2629-3131
Yesi Astri	Department of Neurology, Faculty of Medicine, Universitas Muhammadiyah Palembang, Palembang, Indonesia	yesi_astri@um-palembang.ac.id	0000-0002-5346-5587

Table of COMFORT consortium members (ordered alphabetically by surname).

Full name	Affiliation	E-mail	ORCID
Sameer Bakhshi	Department of Medical Oncology, Dr. B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India	sambakh@hotmail.com	0000-0001-9367-4407
Nuru Y Bayramov	Department of I Surgical Diseases, Azerbaijan Medical University, Baku, Azerbaijan	nurubay2006@yahoo.com	0000-0001-6958-5412
Almir GV Bitencourt	Department of Imaging, A.C.Camargo Cancer Center, São Paulo, Brazil	almir.bitencourt@accamargo.org.br	0000-0003-0192-9885
Anetta Bolejko	Diagnostic Radiology, Department of Translational Medicine, Lund University, Malmö, Sweden; Department of Medical Imaging and Physiology, Skåne University Hospital, Malmö, Sweden	anetta.bolejko@med.lu.se	0000-0002-2963-1119
Antonio J Bolas Becerra	Department of Cardiology, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain	antonio.bollas@quironsalud.es	0000-0003-4612-3949
Ameni Bouattour	Department of Obstetrics and Gynecology, CHU Hedi Chaker, Sfax, Tunisia	ameni.bouattour@gmail.com	0000-0003-3476-1353
Joe Bwambale	Society of Radiography of Uganda, Mulago National Referral Hospital, Mulago, Kampala, Uganda	bwajoe25@gmail.com	-
Andreia Capela	Department of Medical Oncology, Centro Hospitalar Vila Nova de Gaia-Espinho, Vila Nova de Gaia, Portugal; Associação de Investigação de Cuidados de Suporte em Oncologia (AICSO), Vila Nova de Gaia, Portugal	andreia.capela@gmail.com	0000-0002-7576-6938
Riccardo Cau	Department of Radiology, Azienda Ospedaliero Universitaria (A.O.U.), di Cagliari - Polo di Monserrato s.s. 554 Monserrato, Cagliari, Italy	riccardocau00@gmail.com	0000-0002-7910-1087
Kelly R Chacon-Acevedo	Instituto Global de Excelencia Clínica, Grupo de investigación Traslacional, Keralty, Bogotá D.C., Colombia	krchacon@keralty.com	0000-0003-4843-7036
Tafadzwa L Chaunzwa	Departments of Radiation Oncology and Radiology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA, USA	tafadzwa_chaunzwa@dfci.harvard.edu	-
Rubens Chojniak	Department of Imaging, A.C.Camargo Cancer Center, São Paulo, Brazil	chojniak@accamargo.org.br	0000-0002-8096-252X
Warren Clements	Department of Radiology, Alfred Health, Melbourne, Victoria, Australia; Department of Surgery, Monash University, Central Clinical School, Melbourne, Victoria, Australia; National Trauma Research Institute, Melbourne, Victoria, Australia	w.clements@alfred.org.au	0000-0003-1859-5850
Renato Cuocolo	Department of Medicine, Surgery and Dentistry, University of Salerno, Baronissi, Italy	rcuocolo@unisa.it	0000-0002-1452-1574
Victor Dahlblom	Diagnostic Radiology, Department of Translational Medicine, Lund University, Malmö, Sweden	victor.dahlblom@med.lu.se	0000-0002-4330-5387
Kelienny de Meneses Sousa Freitas	Department of Collective Health, Federal University of Rio Grande do Norte, Natal, Brazil	kelienny@gmail.com	0000-0001-6842-7033
Guillermo de Velasco	Department of Biochemistry and Molecular Biology, School of Biology, Complutense University, Madrid, Spain; Instituto de Investigaciones Sanitarias San Carlos (IdISSC), Madrid, Spain	gdvelasco.gdv@gmail.com	0000-0002-1994-2386
Vijay B Desai	Department of Clinical Sciences, College of Dentistry, Ajman University, Ajman, United Arab Emirates	v.desai@ajman.ac.ae	0000-0003-3256-4778
Ajaya K Dhakal	Department of Pediatrics, KIST Medical College and Teaching Hospital, Kathmandu, Nepal	ajayakdhakal@gmail.com	0000-0002-2881-655X
Virginia Dignum	Department of Computing Science, Umeå University, Umeå, Sweden	virginia@cs.umu.se	0000-0001-7409-5813

Table of COMFORT consortium members (ordered alphabetically by surname).

Full name	Affiliation	E-mail	ORCID
Rubens G Feijo Andrade	Department of Radiology, Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, Brazil	rubensfeijoandrade@gmail.com	-
Giovanna Ferraioli	Department of Clinical, Surgical Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy	giovanna.ferraioli@unipv.it	0000-0002-6344-697X
Shuvadeep Ganguly	Department of Medical Oncology, Dr. B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India	ganguly.shuvadeep@gmail.com	0000-0002-7296-6088
Harshit Garg	Department of Urology, Oncology and Robotic Surgery, Max Institute of Cancer Care, Vaishali, Delhi, India	hgarg3108@gmail.com	-
Cvetanka Gjerakaroska Savevska	University Clinic for Physical Medicine and Rehabilitation, Ss Cyril and Methodius University, Skopje, Republic of North Macedonia	cecegerakaroska@yahoo.com	0000-0002-2328-4873
Marija Gjerakaroska Radovikj	University Clinic for State Cardiac Surgery, Ss Cyril and Methodius University, Skopje, Republic of North Macedonia	marijagerakaroska@yahoo.com	0000-0003-4916-6178
Anastasia Gkartzoni	Lab of Medical Physics & Digital Innovation, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece	anastasiagartzoni@gmail.com	-
Luis Gorospe	Department of Radiology, Ramón y Cajal University Hospital, IRYCIS, Madrid, Spain	luisgorospe@yahoo.com	0000-0002-2305-7064
Ian Griffin	Department of Radiology, University of Florida, Gainesville, FL, USA	ian.griffin@ufl.edu	0009-0006-6565-4971
Martin Hadamitzky	Institute for Radiology and Nuclear Medicine, German Heart Center Munich, Technical University of Munich, Munich, Germany	mhh@dhm.mhn.de	0000-0001-6267-1692
Martin Hakorimana Ndahiro	Ministry of Health, Byumba Hospital, Byumba, Rwanda	ndahirolili@gmail.com	0009-0007-4973-4506
Alessa Hering	Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands; Fraunhofer MEVIS, Institute for Digital Medicine, Bremen, Germany	alessa.hering@radboudumc.nl	0000-0002-7602-803X
Bruno Hochhegger	Department of Radiology, University of Florida, Gainesville, FL, USA	bhochhegger@ufl.edu	0000-0003-1984-4636
Mehriban R Huseynova	Department of I Surgical Diseases, Azerbaijan Medical University, Baku, Azerbaijan	mehribanhuseynova9@gmail.com	0000-0002-4040-5868
Fujimaro Ishida	Department of Neurosurgery, Mie Chuo Medical Center, Tsu, Japan	nsfujii@me.com	0000-0002-0525-7636
Nisha Jha	Clinical Pharmacology and Therapeutics, KIST Medical College and Teaching Hospital, Kathmandu, Nepal	nishajha32@gmail.com	0000-0003-1089-6042
Lili Jiang	Department of Computing Science, Umeå University, Umeå, Sweden	lili.jiang@umu.se	0000-0002-7788-3986
Rawen Kader	Division of Surgery and Interventional Sciences, University College London, London, United Kingdom	rawen.kader.17@ucl.ac.uk	0000-0001-9133-0838
Helen Kavnoudias	Department of Radiology, Alfred Health, Melbourne, Victoria, Australia; Department of Surgery, Monash University, Central Clinical School, Melbourne, Victoria, Australia; National Trauma Research Institute, Melbourne, Victoria, Australia; Department of Neuroscience, Monash University, Central Clinical School, Melbourne, Victoria, Australia	h.kavnoudias@alfred.org.au	0000-0001-7686-6802
Clément Klein	Department of Urology, Bordeaux Pellegrin University Hospital, Bordeaux, France	clement.klein@chu-bordeaux.fr	0000-0003-1839-5875

Table of COMFORT consortium members (ordered alphabetically by surname).

Full name	Affiliation	E-mail	ORCID
George Kolostoumpis	European Cancer Patient Coalition (ECPC), Brussels, Belgium	george.kolostoumpis@ecpc.org	0000-0001-9768-9526
Abraham Koshy	Department of Gastroenterology, Lakeshore Hospital, Kochi, India	koshyabe@yahoo.com	0000-0002-9997-6569
Nicholas A Kruger	Orthopaedic Department, University of Cape Town, Cape Town, South Africa	nicholas.kruger@uct.ac.za	0000-0002-8543-5745
Alexander Loeser	Berlin University of Applied Sciences and Technology (BHT), Berlin, Germany	aloeser@bht-berlin.de	0000-0002-4440-3261
Marko Lucijanic	Department of Hematology, Clinical Hospital Dubrava, Zagreb, Croatia; Department of Internal Medicine, School of Medicine, University of Zagreb, Zagreb, Croatia	markolucijanic@yahoo.com	0000-0002-1372-2040
Despoina Mantziari	Lab of Medical Physics & Digital Innovation, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece	mantziad@gmail.com	0000-0003-0964-6417
Gaëlle Margue	Department of Urology, Bordeaux Pellegrin University Hospital, Bordeaux, France	gaëlle.margue@chu-bordeaux.fr	0000-0001-5311-1597
Sonyia McFadden	School of Health Sciences, Londonderry, Northern Ireland, United Kingdom	s.mcfadden@ulster.ac.uk	0000-0002-4001-7769
Masahiro Miyake	Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan	miyakem@kuhp.kyoto-u.ac.jp	0000-0001-7410-3764
Wipawee Morakote	Department of Radiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand	wipawee.m@cmu.ac.th	0000-0002-8670-7386
Issa Ngabonziza	Ministry of Health, Byumba Hospital, Byumba, Rwanda	ingabonziza@gmail.com	0000-0001-6092-166X
Thao T Nguyen	Department of Radiology, University of Medicine and Pharmacy, Hue University, Hue, Vietnam	nthao@hueuni.edu.vn	0000-0001-9379-6359
Stefan M Niehues	Department of Radiology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany	stefan.niehues@charite.de	0000-0001-6140-9385
Marc Nortje	Orthopaedic Department, University of Cape Town, Cape Town, South Africa	mbnortje1@gmail.com	0000-0002-7737-409X
Subish Palaian	Department of Clinical Sciences, College of Pharmacy and Health Sciences, Ajman University, Ajman, United Arab Emirates	subishpalaian@gmail.com	0000-0002-9323-3940
Natalia V Pentara	Department of Clinical Radiology, AHEPA General University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece	navapent@gmail.com	0000-0002-4747-185X
Rui P Pereira de Almeida	Department of Radiology, University of Algarve, Faro, Portugal; Comprehensive Health Research Center, University of Évora, Évora, Portugal	rpalmeida@ualg.pt	0000-0001-7524-9669
Gianluigi Poma	Department of Diagnostic and Imaging Services, Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy	gl.poma@smatteo.pv.it	0009-0006-2040-1858
Mitayani Purwoko	Medical Biology, Faculty of Medicine Universitas Muhammadiyah Palembang, Palembang, Indonesia	mitayani@um-palembang.ac.id	0000-0002-3936-3883
Nikolaos Pyrgidis	Department of Urology, University Hospital, Ludwig-Maximilians-University of Munich, Munich, Germany	nikolaos.pyrgidis@med.uni-muenchen.de	0000-0002-7707-8426
Vasileios Rafailidis	Department of Clinical Radiology, AHEPA General University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece	billraf@hotmail.com	0000-0002-0284-4106
Clare Rainey	School of Health Sciences, Londonderry, Northern Ireland, United Kingdom	c.rainey@ulster.ac.uk	0000-0003-0449-8646

Table of COMFORT consortium members (ordered alphabetically by surname).

Full name	Affiliation	E-mail	ORCID
João C Ribeiro	Department of Otolaryngology, Coimbra University and Medical School, Coimbra, Portugal	jcarlosribeiro@uc.pt	0000-0002-1039-6358
Nicolás Rozo Agudelo	Instituto Global de Excelencia Clínica, Grupo de investigación Traslacional, Keralty, Bogotá D.C., Colombia	nrozo@colsanitas.com	0000-0003-0409-2515
Keina Sado	Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan	keina_sado@kuhp.kyoto-u.ac.jp	0009-0002-7596-4325
Julia M Saidman	Department of Radiology, Hospital Italiano de Buenos Aires, Ciudad Autónoma de Buenos Aires, Argentina	julia.saidman@hospitalitaliano.org.ar	0000-0002-7626-7356
Pedro J Saturno-Hernandez	AXA Chair in Healthcare Quality, CIEE, National Institute of Public Health, Cuernavaca, Mexico	pedro.saturno@insp.mx	0000-0002-4991-5805
Vidyani Suryadevara	Department of Radiology, Molecular Imaging Program at Stanford (MIPS), Stanford University School of Medicine, Stanford, CA, USA	vidyani@stanford.edu	0000-0003-4081-2989
Gerald B Schulz	Department of Urology, University Hospital, Ludwig-Maximilians-University of Munich, Munich, Germany	gerald.schulz@med.uni-muenchen.de	-
Ena Soric	Department of Hematology, Clinical Hospital Dubrava, Zagreb, Croatia	enasoric9@gmail.com	0009-0007-9831-1905
Javier Soto-Pérez-Olivares	Department of Radiology, Ramón y Cajal University Hospital, IRYCIS, Madrid, Spain	javiersoto94@gmail.com	0000-0002-0858-1394
Arnaldo Stanzione	Department of Advanced Biomedical Sciences, University of Naples "Federico II", Naples, Italy	arnaldo.stanzione@unina.it	0000-0002-7905-5789
Julian P Struck	Department of Urology, Faculty of Health Sciences Brandenburg, Brandenburg Medical School Theodor Fontane, Brandenburg a.d. Havel, Germany	julian.struck@uk-brandenburg.de	-
Hiroyuki Takaoka	Department of Cardiology, Chiba University Hospital, Chiba, Japan	tapy21century@yahoo.co.jp	0000-0001-8745-2162
Satoru Tanioka	Department of Neurosurgery, Mie University Graduate School of Medicine, Tsu, Japan; Charité Lab for Artificial Intelligence in Medicine, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany	satoru.tanioka.ns@icloud.com	0000-0002-4678-6163
Tran TM Huyen	Department of Radiology, University of Medicine and Pharmacy, Hue University, Hue, Vietnam	ttmhuyen@huemed-univ.edu.vn	0000-0002-0005-0150
Daniel Truhn	Department of Diagnostic and Interventional Radiology, University Hospital Aachen, Aachen, Germany	dtruhn@ukaachen.de	0000-0002-9605-0728
Elon HC van Dijk	Department of Ophthalmology, Leiden University Medical Center, Leiden, The Netherlands; Department of Ophthalmology, Alrijne Hospital, Leiderdorp, The Netherlands	ehcvandijk@lumc.nl	0000-0002-6351-7942
Peter van Wijngaarden	Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne, Victoria, Australia; Ophthalmology, Department of Surgery, University of Melbourne, Melbourne, Victoria, Australia	peterv@unimelb.edu.au	0000-0002-8800-7834
Yuan-Cheng Wang	Department of Radiology, Zhongda Hospital Southeast University, Nanjing, China	yuancheng_wang@seu.edu.cn	0000-0001-6800-6650
Matthias Weidlich	Department of Radiology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany	matthias.weidlich@charite.de	0000-0001-6152-3874
Shuhang Zhang	Department of Radiology, Zhongda Hospital Southeast University, Nanjing, China	shuhangzhang@outlook.com	0009-0008-1459-2824

Members are listed in alphabetical order by surname.

Competing Interests Statement

The authors declare the following competing interests: Petros Sountoulides, Keno K Bressem, Renato Cuocolo, Virginia Dignum, Guillermo de Velasco, Alessa Hering, Lili Jiang, George Kolostoumpis, and Alexander Loeser report research grants from the European Commission (101079894); Keno K Bressem reports grants from the Wilhelm Sander Foundation and speaker fees from Canon Medical Systems Corporation and GE Healthcare, and is a member of the advisory board of the EU Horizon 2020 LifeChamps project (875329) and the EU IHI project IMAGIO (101112053); Martina Aineseder reports consultant fees from Segmed, Inc.; Giovanna Ferraioli reports speaker honoraria from Canon Medical Systems, Fujifilm Healthcare, Mindray Healthcare, Philips Healthcare, and Siemens Healthineers, is an advisory board member for Philips Healthcare and Siemens Healthineers and receives royalties from Elsevier; Giovanna Ferraioli's university received equipment grants and unrestricted research grants from Canon Medical Systems, Philips Ultrasound, and Siemens Healthineers. None of the other authors declares potential conflicts of interest.

References

1. Peres, R.S., *et al.* Industrial Artificial Intelligence in Industry 4.0 - Systematic Review, Challenges and Outlook. *IEEE Access* **8**, 220121-220139 (2020).
2. Collins, C., Dennehy, D., Conboy, K. & Mikalef, P. Artificial intelligence in information systems research: A systematic literature review and research agenda. *International Journal of Information Management* **60**, 102383 (2021).
3. McCarthy, J., Minsky, M., Rochester, N. & Shannon, C. A Proposal for the Dartmouth Summer Research Project on Artificial Intelligence, August 31, 1955. *AI Magazine* **27**, 12-14 (2006).
4. Choudhury, A. & Shamszare, H. Investigating the Impact of User Trust on the Adoption and Use of ChatGPT: Survey Analysis. *J Med Internet Res* **25**, e47184 (2023).
5. Chan, S.C.C., Neves, A.L., Majeed, A. & Faisal, A. Bridging the equity gap towards inclusive artificial intelligence in healthcare diagnostics. Vol. 384 (British Medical Journal Publishing Group, 2024).
6. Davenport, T. & Kalakota, R. The potential for artificial intelligence in healthcare. *Future Healthc J* **6**, 94-98 (2019).
7. Jiang, F., *et al.* Artificial intelligence in healthcare: past, present and future. *Stroke Vasc Neurol* **2**, 230-243 (2017).
8. Ferrari, R., *et al.* MR-based artificial intelligence model to assess response to therapy in locally advanced rectal cancer. *European Journal of Radiology* **118**, 1-9 (2019).
9. Bai, W., *et al.* A population-based phenome-wide association study of cardiac and aortic structure and function. *Nature medicine* **26**, 1654-1662 (2020).
10. Paul, D., *et al.* Artificial intelligence in drug discovery and development. *Drug Discov Today* **26**, 80-93 (2021).
11. Adams, L.C., *et al.* Leveraging GPT-4 for Post Hoc Transformation of Free-Text Radiology Reports into Structured Reporting: A Multilingual Feasibility Study. *Radiology*, 230725 (2023).
12. Sahni, N.R., Stein, G., Zimmel, R. & Cutler, D.M. The Potential Impact of Artificial Intelligence on Healthcare Spending. in *The Economics of Artificial Intelligence: Health Care Challenges* (eds. Agrawal, A., Gans, J., Goldfarb, A. & Tucker, C.T.) 192 (University of Chicago Press, Chicago, IL, USA, 2024).
13. (FDA), F.a.D.A. Artificial Intelligence and Machine Learning (AI/ML)-Enabled Medical Devices. (2023).

14. Ethics and governance of artificial intelligence for health: WHO guidance: executive summary. 11 (Geneva: World Health Organization, 2021).
15. Sauerbrei, A., Kerasidou, A., Lucivero, F. & Hallowell, N. The impact of artificial intelligence on the person-centred, doctor-patient relationship: some problems and solutions. *BMC Medical Informatics and Decision Making* **23**, 73 (2023).
16. Adus, S., Macklin, J. & Pinto, A. Exploring patient perspectives on how they can and should be engaged in the development of artificial intelligence (AI) applications in health care. *BMC Health Services Research* **23**, 1163 (2023).
17. Holtz, B., Nelson, V. & Poropatich, R.K. Artificial Intelligence in Health: Enhancing a Return to Patient-Centered Communication. *Telemed J E Health* **29**, 795-797 (2023).
18. Bjerring, J.C. & Busch, J. Artificial Intelligence and Patient-Centered Decision-Making. *Philosophy & Technology* **34**, 349-371 (2021).
19. Yu, F., *et al.* Heterogeneity and predictors of the effects of AI assistance on radiologists. *Nature Medicine*, 1-13 (2024).
20. Rosen, R. How is technology changing clinician-patient relationships? , Vol. 384 (British Medical Journal Publishing Group, 2024).
21. Bobak, C.A., Svoboda, M., Giffin, K.A., Wall, D.P. & Moore, J. Raising the stakeholders: Improving patient outcomes through interprofessional collaborations in AI for healthcare. in *Pacific Symposium on Biocomputing 2021*, Vol. 26 351-355 (2020).
22. Martin, L.R., Williams, S.L., Haskard, K.B. & DiMatteo, M.R. The challenge of patient adherence. *Therapeutics and clinical risk management* **1**, 189-199 (2005).
23. Lee, Y.-Y. & Lin, J.L. How much does trust really matter? A study of the longitudinal effects of trust and decision-making preferences on diabetic patient outcomes. *Patient education and counseling* **85**, 406-412 (2011).
24. Young, A.T., Amara, D., Bhattacharya, A. & Wei, M.L. Patient and general public attitudes towards clinical artificial intelligence: a mixed methods systematic review. *The Lancet Digital Health* **3**, e599-e611 (2021).
25. Robertson, C., *et al.* Diverse patients' attitudes towards Artificial Intelligence (AI) in diagnosis. *PLOS Digital Health* **2**, e0000237 (2023).
26. Fritsch, S.J., *et al.* Attitudes and perception of artificial intelligence in healthcare: A cross-sectional survey among patients. *DIGITAL HEALTH* **8**, 20552076221116772 (2022).

27. Armero, W., *et al.* A survey of pregnant patients' perspectives on the implementation of artificial intelligence in clinical care. *Journal of the American Medical Informatics Association* **30**, 46-53 (2022).
28. Ibba, S., *et al.* How do patients perceive the AI-radiologists interaction? Results of a survey on 2119 responders. *Eur J Radiol* **165**, 110917 (2023).
29. Khullar, D., *et al.* Perspectives of Patients About Artificial Intelligence in Health Care. *JAMA Network Open* **5**, e2210309-e2210309 (2022).
30. Parry, M.W., *et al.* Patient Perspectives on Artificial Intelligence in Healthcare Decision Making: A Multi-Center Comparative Study. *Indian J Orthop* **57**, 653-665 (2023).
31. Yap, A., *et al.* Patients Perceptions of Artificial Intelligence in Diabetic Eye Screening. *Asia Pac J Ophthalmol (Phila)* **11**, 287-293 (2022).
32. Wickham, H., *et al.* Welcome to the Tidyverse. *Journal of Open Source Software* **4**, 1686 (2019).
33. Rosseel, Y. lavaan: An R Package for Structural Equation Modeling. *Journal of Statistical Software* **48**, 1 - 36 (2012).
34. Revelle, W. *psych: Procedures for Psychological, Psychometric, and Personality Research [version 2.2.9]*. <https://CRAN.R-project.org/package=psych>. Published September 29, 2022. Accessed January 10, 2023.
35. Christensen, R. *ordinal—Regression Models for Ordinal Data [version 2023.12-4]*. <https://CRAN.R-project.org/package=ordinal>. Published September 29, 2022. Accessed May 12, 2024.
36. Bates, D., Mächler, M., Bolker, B., & Walker, S. Fitting Linear Mixed-Effects Models Using lme4. *J Stat Softw* **67**, 1-48 (2015).
37. United Nations, Finance Center for South-South Cooperation. *Global South Countries (Group of 77 and China)*. http://www.fc-ssc.org/en/partnership_program/south_south_countries. Published 2015. Accessed October 7, 2023.
38. United Nations, Department of Economic and Social Affairs, Statistics Division. *Standard Country or Area Codes for Statistics Use, 1999 (Revision 4)* (United Nations, 1999).
39. Jutzi, T.B., *et al.* Artificial Intelligence in Skin Cancer Diagnostics: The Patients' Perspective. *Frontiers in Medicine* **7**(2020).
40. Wolf, R.M., *et al.* Potential reduction in healthcare carbon footprint by autonomous artificial intelligence. *NPJ digital medicine* **5**, 62 (2022).

41. Saenz, A.D., Harned, Z., Banerjee, O., Abramoff, M.D. & Rajpurkar, P. Autonomous AI systems in the face of liability, regulations and costs. *NPJ digital medicine* **6**, 185 (2023).
42. Abramoff, M.D., *et al.* Autonomous artificial intelligence increases real-world specialist clinic productivity in a cluster-randomized trial. *NPJ digital medicine* **6**, 184 (2023).
43. Lennartz, S., *et al.* Use and Control of Artificial Intelligence in Patients Across the Medical Workflow: Single-Center Questionnaire Study of Patient Perspectives. *J Med Internet Res* **23**, e24221 (2021).
44. Yang, K., Zeng, Z., Peng, H. & Jiang, Y. Attitudes Of Chinese Cancer Patients Toward The Clinical Use Of Artificial Intelligence. *Patient Prefer Adherence* **13**, 1867-1875 (2019).

Figures




Fig. 1. Geographical distribution of participating institutions (blue dots) on a world map.

Legend: The size of the blue dots refers to the proportion of respondents per institution relative to the total number of respondents. Countries with at least one participating institution are highlighted in dark green. A, North America; B, Europe; C, Africa; D, South America; E, Asia; F, Australia.




Fig. 2. Gantt diagrams depicting the results for each item for the total study cohort.

Legend: Colors represent the response options indicated below each Gantt chart, including the corresponding numerator and denominator.

Tables

Table 1 Sociodemographic data and scores on technological literacy, health status, and AI knowledge items for the total study population and regional breakdowns by Global North/South and continents.

	Total (N=13806)	Global North (N=8951)	Global South (N=4855)	Europe (N=5764)	Asia (N=3473)	North America (N=2284)	South America (N=1336)	Africa (N=728)	Oceania (N=221)
Gender, no. (%)	-	-	-	-	-	-	-	-	-
Female	6451 (46.73%)	4163 (46.51%)	2288 (47.13%)	2636 (45.73%)	1472 (42.38%)	1101 (48.2%)	809 (60.55%)	342 (46.98%)	91 (41.18%)
Male	6973 (50.51%)	4639 (51.83%)	2334 (48.07%)	3008 (52.19%)	1812 (52.17%)	1137 (49.78%)	516 (38.62%)	375 (51.51%)	125 (56.56%)
Diverse	32 (0.23%)	22 (0.25%)	10 (0.21%)	18 (0.31%)	4 (0.12%)	2 (0.09%)	2 (0.15%)	4 (0.55%)	2 (0.9%)
Not reported	350 (2.54%)	127 (1.42%)	223 (4.59%)	102 (1.77%)	185 (5.33%)	44 (1.93%)	9 (0.67%)	7 (0.96%)	3 (1.36%)
Age	-	-	-	-	-	-	-	-	-
Median (IQR), y	48 (34-62)	54 (39-66)	39 (28-52)	55 (39-67)	45 (31-59)	48 (36-61)	42 (30-55)	32 (25-42)	55 (37-66)
Not reported, no. (%)	1354 (9.81%)	877 (9.8%)	477 (9.82%)	639 (11.09%)	392 (11.29%)	226 (9.89%)	62 (4.64%)	22 (3.02%)	13 (5.88%)
Highest educational level, no. (%)	-	-	-	-	-	-	-	-	-
Elementary School Diploma	1192 (8.63%)	780 (8.71%)	412 (8.49%)	684 (11.87%)	224 (6.45%)	96 (4.2%)	139 (10.4%)	39 (5.36%)	10 (4.52%)
Middle School Diploma	2844 (20.6%)	1868 (20.87%)	976 (20.1%)	1416 (24.57%)	463 (13.33%)	448 (19.61%)	464 (34.73%)	46 (6.32%)	7 (3.17%)
High School Diploma	4142 (30%)	2790 (31.17%)	1352 (27.85%)	1431 (24.83%)	998 (28.74%)	946 (41.42%)	449 (33.61%)	229 (31.46%)	89 (40.27%)
University Degree	5403 (39.14%)	3346 (37.38%)	2057 (42.37%)	2089 (36.24%)	1747 (50.3%)	776 (33.98%)	277 (20.73%)	402 (55.22%)	112 (50.68%)
Not reported	225 (1.63%)	167 (1.87%)	58 (1.19%)	144 (2.5%)	41 (1.18%)	18 (0.79%)	7 (0.52%)	12 (1.65%)	3 (1.36%)
Use of technical devices ^a	-	-	-	-	-	-	-	-	-
Median (IQR), total no.	2 (1-3)	2 (1-3)	1 (1-2)	2 (1-3)	1 (1-2)	2 (1-3)	2 (1-2)	1 (1-2)	2 (2-3)
Smartphone, no. (%)	12554 (90.93%)	8092 (90.4%)	4462 (91.91%)	5154 (89.42%)	3203 (92.23%)	2087 (91.37%)	1244 (93.11%)	661 (90.8%)	205 (92.76%)
PC/laptop, no. (%)	7902 (57.24%)	5724 (63.95%)	2178 (44.86%)	3896 (67.59%)	1400 (40.31%)	1321 (57.84%)	769 (57.56%)	367 (50.41%)	149 (67.42%)
Game console (eg, PlayStation, Switch), no. (%)	924 (6.69%)	609 (6.8%)	315 (6.49%)	361 (6.26%)	200 (5.76%)	196 (8.58%)	104 (7.78%)	40 (5.49%)	23 (10.41%)

	Total (N=13806)	Global North (N=8951)	Global South (N=4855)	Europe (N=5764)	Asia (N=3473)	North America (N=2284)	South America (N=1336)	Africa (N=728)	Oceania (N=221)
Tablet (eg, iPad), no. (%)	3344 (24.22%)	2519 (28.14%)	825 (16.99%)	1620 (28.11%)	595 (17.13%)	748 (32.75%)	209 (15.64%)	103 (14.15%)	69 (31.22%)
E-reader, no. (%)	907 (6.57%)	677 (7.56%)	230 (4.74%)	463 (8.03%)	144 (4.15%)	175 (7.66%)	87 (6.51%)	25 (3.43%)	13 (5.88%)
Smartwatch, no. (%)	2443 (17.7%)	1797 (20.08%)	646 (13.31%)	1183 (20.52%)	423 (12.18%)	495 (21.67%)	222 (16.62%)	56 (7.69%)	64 (28.96%)
None, no. (%)	363 (2.63%)	265 (2.96%)	98 (2.02%)	202 (3.5%)	79 (2.27%)	39 (1.71%)	32 (2.4%)	10 (1.37%)	1 (0.45%)
Not reported, no. (%)	54 (0.39%)	52 (0.58%)	2 (0.04%)	46 (0.8%)	0	6 (0.26%)	1 (0.07%)	1 (0.14%)	0
Health status ^b , no. (%)	-	-	-	-	-	-	-	-	-
Very poor	203 (1.47%)	66 (0.74%)	137 (2.82%)	56 (0.97%)	48 (1.38%)	3 (0.13%)	35 (2.62%)	57 (7.83%)	4 (1.81%)
Poor	1221 (8.84%)	711 (7.94%)	510 (10.5%)	488 (8.47%)	380 (10.94%)	143 (6.26%)	130 (9.73%)	65 (8.93%)	15 (6.79%)
Sufficient	4244 (30.74%)	2798 (31.26%)	1446 (29.78%)	1679 (29.13%)	1319 (37.98%)	652 (28.55%)	454 (33.98%)	107 (14.7%)	33 (14.93%)
Good	5439 (39.4%)	3811 (42.58%)	1628 (33.53%)	2546 (44.17%)	1150 (33.11%)	966 (42.29%)	442 (33.08%)	237 (32.55%)	98 (44.34%)
Very good	2553 (18.49%)	1448 (16.18%)	1105 (22.76%)	891 (15.46%)	559 (16.1%)	502 (21.98%)	273 (20.43%)	258 (35.44%)	70 (31.67%)
Not reported	146 (1.06%)	117 (1.31%)	29 (0.6%)	104 (1.8%)	17 (0.49%)	18 (0.79%)	2 (0.15%)	4 (0.55%)	1 (0.45%)
AI knowledge ^c , no. (%)	-	-	-	-	-	-	-	-	-
No knowledge (never heard of AI)	1848 (13.39%)	927 (10.36%)	921 (18.97%)	629 (10.91%)	692 (19.93%)	219 (9.59%)	194 (14.52%)	97 (13.32%)	17 (7.69%)
Little knowledge (eg, documentary seen on television)	8097 (58.65%)	5459 (60.99%)	2638 (54.34%)	3530 (61.24%)	2075 (59.75%)	1273 (55.74%)	751 (56.21%)	349 (47.94%)	119 (53.85%)
Good knowledge (eg, read several articles about AI)	3423 (24.79%)	2311 (25.82%)	1112 (22.9%)	1414 (24.53%)	649 (18.69%)	724 (31.7%)	306 (22.9%)	251 (34.48%)	79 (35.75%)
Expert (eg, involved in AI development)	211 (1.53%)	131 (1.46%)	80 (1.65%)	80 (1.39%)	36 (1.04%)	47 (2.06%)	17 (1.27%)	25 (3.43%)	6 (2.71%)
Not reported	227 (1.64%)	123 (1.37%)	104 (2.14%)	111 (1.93%)	21 (0.6%)	21 (0.92%)	68 (5.09%)	6 (0.82%)	0

^a Item: Which of these technical devices do you use at least once a week?

^b Item: What is your current general state of health?

^c Item: How would you rate your knowledge of artificial intelligence (AI)?

Abbreviation: IQR, interquartile range.

Table 2. Absolute survey results and regional breakdowns for each item.

	Total (N=13806)	Global North (N=8951)	Global South (N=4855)	Europe (N=5764)	Asia (N=3473)	North America (N=2284)	South America (N=1336)	Africa (N=728)	Oceania (N=221)
Q1, no. (%)	13502 (97.8%)	8787 (98.17%)	4715 (97.12%)	5617 (97.45%)	3427 (98.68%)	2260 (98.95%)	1261 (94.39%)	721 (99.04%)	216 (97.74%)
Extremely negative	296 (2.19%)	137 (1.56%)	159 (3.37%)	86 (1.53%)	78 (2.28%)	33 (1.46%)	31 (2.46%)	63 (8.74%)	5 (2.31%)
Rather negative	1033 (7.65%)	657 (7.48%)	376 (7.97%)	448 (7.98%)	246 (7.18%)	142 (6.28%)	108 (8.56%)	68 (9.43%)	21 (9.27%)
Neutral	4398 (32.57%)	3019 (34.36%)	1379 (29.25%)	1980 (35.25%)	987 (28.8%)	663 (29.34%)	457 (36.24%)	225 (31.21%)	86 (39.81%)
Rather positive	5554 (41.13%)	3787 (43.1%)	1767 (37.48%)	2389 (42.53%)	1384 (40.39%)	1023 (45.27%)	458 (36.32%)	218 (30.24%)	82 (37.96%)
Extremely positive	2221 (16.45%)	1187 (13.51%)	1034 (21.93%)	714 (12.71%)	732 (21.36%)	399 (17.65%)	207 (16.42%)	147 (20.39%)	22 (10.19%)
Q2, no. (%)	13314 (96.44%)	8627 (96.38%)	4687 (96.54%)	5477 (95.02%)	3416 (98.36%)	2167 (94.88%)	1319 (98.73%)	717 (98.49%)	218 (98.64%)
Completely disagree	428 (3.21%)	207 (2.4%)	221 (4.72%)	118 (2.15%)	112 (3.28%)	55 (2.54%)	73 (5.53%)	61 (8.51%)	9 (4.13%)
Tend to disagree	1059 (7.95%)	645 (7.48%)	414 (8.83%)	459 (8.38%)	243 (7.11%)	119 (5.49%)	129 (9.78%)	85 (11.85%)	24 (11.01%)
Neutral	3446 (25.88%)	2480 (28.75%)	966 (20.61%)	1668 (30.45%)	804 (23.54%)	495 (22.84%)	248 (18.8%)	154 (21.48%)	77 (35.32%)
Tend to agree	5162 (38.77%)	3482 (40.36%)	1680 (35.84%)	2200 (40.17%)	1303 (38.14%)	835 (38.53%)	532 (40.33%)	209 (29.15%)	83 (38.07%)
Agree completely	3219 (24.18%)	1813 (21.02%)	1406 (30%)	1032 (18.84%)	954 (27.93%)	663 (30.6%)	337 (25.55%)	208 (29.01%)	25 (11.47%)
Q3, no. (%)	13542 (98.09%)	8753 (97.79%)	4789 (98.64%)	5593 (97.03%)	3423 (98.56%)	2252 (98.6%)	1326 (99.25%)	727 (99.86%)	221 (100%)
Very little	528 (3.9%)	323 (3.69%)	205 (4.28%)	202 (3.61%)	115 (3.36%)	75 (3.33%)	47 (3.54%)	76 (10.45%)	13 (5.88%)
Little	1545 (11.41%)	902 (10.31%)	643 (13.43%)	577 (10.32%)	374 (10.93%)	228 (10.12%)	232 (17.5%)	106 (14.58%)	28 (12.67%)
Medium	4896 (36.15%)	3346 (38.23%)	1550 (32.37%)	2200 (39.33%)	1277 (37.31%)	682 (30.28%)	469 (35.37%)	186 (25.58%)	82 (37.1%)
Much	4566 (33.72%)	3104 (35.46%)	1462 (30.53%)	1993 (35.63%)	987 (28.83%)	895 (39.74%)	422 (31.83%)	213 (29.3%)	56 (25.34%)
Very much	2007 (14.82%)	1078 (12.32%)	929 (19.4%)	621 (11.1%)	670 (19.57%)	372 (16.52%)	156 (11.76%)	146 (20.08%)	42 (19%)
Q4, no. (%)	13507 (97.83%)	8730 (97.53%)	4777 (98.39%)	5573 (96.69%)	3420 (98.47%)	2245 (98.29%)	1323 (99.03%)	726 (99.73%)	220 (99.55%)

Table 2. Absolute survey results and regional breakdowns for each item.

	Total (N=13806)	Global North (N=8951)	Global South (N=4855)	Europe (N=5764)	Asia (N=3473)	North America (N=2284)	South America (N=1336)	Africa (N=728)	Oceania (N=221)
Very little	564 (4.18%)	359 (4.11%)	205 (4.29%)	219 (3.93%)	97 (2.84%)	98 (4.37%)	58 (4.38%)	74 (10.19%)	18 (8.18%)
Little	1859 (13.76%)	1083 (12.41%)	776 (16.24%)	719 (12.9%)	478 (13.98%)	275 (12.25%)	249 (18.82%)	104 (14.33%)	34 (15.45%)
Medium	5149 (38.12%)	3569 (40.88%)	1580 (33.08%)	2455 (44.05%)	1158 (33.86%)	721 (32.12%)	501 (37.87%)	227 (31.27%)	87 (39.55%)
Much	4587 (33.96%)	3075 (35.22%)	1512 (31.65%)	1804 (32.37%)	1196 (34.97%)	906 (40.36%)	399 (30.16%)	218 (30.03%)	64 (29.09%)
Very much	1348 (9.98%)	644 (7.38%)	704 (14.74%)	376 (6.75%)	491 (14.36%)	245 (10.91%)	116 (8.77%)	103 (14.19%)	17 (7.73%)
Q5, no. (%)	13496 (97.75%)	8716 (97.37%)	4780 (98.46%)	5561 (96.48%)	3426 (98.65%)	2242 (98.16%)	1322 (98.95%)	726 (99.73%)	219 (99.1%)
Very little	597 (4.42%)	401 (4.6%)	196 (4.1%)	236 (4.24%)	106 (3.09%)	112 (5%)	61 (4.61%)	60 (8.26%)	22 (10.05%)
Little	1919 (14.22%)	1110 (12.74%)	809 (16.92%)	750 (13.49%)	473 (13.81%)	282 (12.58%)	253 (19.14%)	134 (18.46%)	27 (12.33%)
Medium	5093 (37.74%)	3514 (40.32%)	1579 (33.03%)	2395 (43.07%)	1156 (33.74%)	746 (33.27%)	483 (36.54%)	225 (30.99%)	88 (40.18%)
Much	4516 (33.46%)	3027 (34.73%)	1489 (31.15%)	1796 (32.3%)	1216 (35.49%)	846 (37.73%)	392 (29.65%)	206 (28.37%)	60 (27.4%)
Very much	1371 (10.16%)	664 (7.62%)	707 (14.79%)	384 (6.91%)	475 (13.86%)	256 (11.42%)	133 (10.06%)	101 (13.91%)	22 (10.05%)
Q6, no. (%)	13480 (97.64%)	8704 (97.24%)	4776 (98.37%)	5551 (96.3%)	3423 (98.56%)	2238 (97.99%)	1322 (98.95%)	726 (99.73%)	220 (99.55%)
Very little	614 (4.55%)	424 (4.87%)	190 (3.98%)	261 (4.7%)	105 (3.07%)	113 (5.05%)	50 (3.78%)	63 (8.68%)	22 (10%)
Little	1962 (14.55%)	1183 (13.59%)	779 (16.31%)	777 (14%)	459 (13.41%)	308 (13.76%)	252 (19.06%)	123 (16.94%)	43 (19.55%)
Medium	5267 (39.07%)	3601 (41.37%)	1666 (34.88%)	2493 (44.91%)	1209 (35.32%)	723 (32.31%)	522 (39.49%)	243 (33.47%)	77 (35%)
Much	4346 (32.24%)	2894 (33.25%)	1452 (30.4%)	1675 (30.17%)	1187 (34.68%)	853 (38.11%)	381 (28.82%)	191 (26.31%)	59 (26.82%)
Very much	1291 (9.58%)	602 (6.92%)	689 (14.43%)	345 (6.22%)	463 (13.53%)	241 (10.77%)	117 (8.85%)	106 (14.6%)	19 (8.64%)
Q7, no. (%)	13139 (95.17%)	8439 (94.28%)	4700 (96.81%)	5361 (93.01%)	3381 (97.35%)	2179 (95.4%)	1298 (97.16%)	711 (97.66%)	209 (94.57%)
No use of AI independent of the disease.	1499 (11.41%)	876 (10.38%)	623 (13.26%)	546 (10.18%)	388 (11.48%)	237 (10.88%)	174 (13.41%)	131 (18.42%)	23 (11%)

Table 2. Absolute survey results and regional breakdowns for each item.

	Total (N=13806)	Global North (N=8951)	Global South (N=4855)	Europe (N=5764)	Asia (N=3473)	North America (N=2284)	South America (N=1336)	Africa (N=728)	Oceania (N=221)
Use only for minor illnesses (eg, cold).	3661 (27.86%)	2101 (24.9%)	1560 (33.19%)	1366 (25.48%)	1094 (32.36%)	509 (23.36%)	444 (34.21%)	198 (27.85%)	50 (23.92%)
Use also for moderately severe diseases (eg, appendicitis).	3510 (26.71%)	2336 (27.68%)	1174 (24.98%)	1444 (26.94%)	947 (28.01%)	643 (29.51%)	247 (19.03%)	168 (23.63%)	61 (29.19%)
Use also for severe diseases (eg, cancer, traffic accidents).	4469 (34.01%)	3126 (37.04%)	1343 (28.57%)	2005 (37.4%)	952 (28.16%)	790 (36.26%)	433 (33.36%)	214 (30.1%)	75 (35.89%)
Q8, no. (%)	13437 (97.33%)	8668 (96.84%)	4769 (98.23%)	5522 (95.8%)	3423 (98.56%)	2225 (97.42%)	1323 (99.03%)	725 (99.59%)	219 (99.1%)
Completely disagree	1411 (10.5%)	984 (11.35%)	427 (8.95%)	677 (12.26%)	123 (3.59%)	236 (10.61%)	258 (19.5%)	80 (11.03%)	37 (16.89%)
Tend to disagree	2609 (19.42%)	1829 (21.1%)	780 (16.36%)	1235 (22.37%)	443 (12.94%)	475 (21.35%)	281 (21.24%)	136 (18.76%)	39 (17.81%)
Neutral	3659 (27.23%)	2502 (28.86%)	1157 (24.26%)	1630 (29.52%)	988 (28.86%)	511 (22.97%)	267 (20.18%)	201 (27.72%)	62 (28.31%)
Tend to agree	4374 (32.55%)	2716 (31.33%)	1658 (34.77%)	1590 (28.79%)	1339 (39.12%)	776 (34.88%)	388 (29.33%)	212 (29.24%)	69 (31.51%)
Agree completely	1384 (10.3%)	637 (7.35%)	747 (15.66%)	390 (7.06%)	530 (15.48%)	227 (10.2%)	129 (9.75%)	96 (13.24%)	12 (5.48%)
Q9, no. (%)	12986 (94.06%)	8243 (92.09%)	4743 (97.69%)	5134 (89.07%)	3401 (97.93%)	2196 (96.15%)	1317 (98.58%)	722 (99.18%)	216 (97.74%)
Extremely negative	381 (2.93%)	191 (2.32%)	190 (4.01%)	105 (2.05%)	105 (3.09%)	54 (2.46%)	52 (3.95%)	57 (7.89%)	8 (3.7%)
Rather negative	1226 (9.44%)	685 (8.31%)	541 (11.41%)	470 (9.15%)	268 (7.88%)	162 (7.38%)	237 (18%)	69 (9.56%)	20 (9.26%)
Neutral	3682 (28.35%)	2318 (28.12%)	1364 (28.76%)	1475 (28.73%)	1093 (32.14%)	528 (24.04%)	336 (25.51%)	190 (26.32%)	60 (27.78%)
Rather positive	5303 (40.84%)	3726 (45.2%)	1577 (33.25%)	2292 (44.64%)	1223 (35.96%)	970 (44.17%)	475 (36.07%)	242 (33.52%)	101 (46.76%)
Extremely positive	2394 (18.44%)	1323 (16.05%)	1071 (22.58%)	792 (15.43%)	712 (20.94%)	482 (21.95%)	217 (16.48%)	164 (22.71%)	27 (12.5%)
Q10, no. (%)	12953 (93.82%)	8219 (91.82%)	4734 (97.51%)	5110 (88.65%)	3399 (97.87%)	2192 (95.97%)	1314 (98.35%)	721 (99.04%)	217 (98.19%)
Extremely negative	567 (4.38%)	323 (3.93%)	244 (5.15%)	211 (4.13%)	118 (3.47%)	79 (3.6%)	84 (6.39%)	63 (8.74%)	12 (5.53%)
Rather negative	1581 (12.21%)	868 (10.56%)	713 (15.06%)	597 (11.68%)	433 (12.74%)	194 (8.85%)	248 (18.87%)	71 (9.85%)	38 (17.51%)

Table 2. Absolute survey results and regional breakdowns for each item.

	Total (N=13806)	Global North (N=8951)	Global South (N=4855)	Europe (N=5764)	Asia (N=3473)	North America (N=2284)	South America (N=1336)	Africa (N=728)	Oceania (N=221)
Neutral	3732 (28.81%)	2354 (28.64%)	1378 (29.11%)	1477 (28.9%)	1037 (30.51%)	584 (26.64%)	351 (26.71%)	222 (30.79%)	61 (28.11%)
Rather positive	4909 (37.9%)	3431 (41.74%)	1478 (31.22%)	2091 (40.92%)	1190 (35.01%)	895 (40.83%)	438 (33.33%)	219 (30.37%)	76 (35.02%)
Extremely positive	2164 (16.71%)	1243 (15.12%)	921 (19.46%)	734 (14.36%)	621 (18.27%)	440 (20.07%)	193 (14.69%)	146 (20.25%)	30 (13.82%)
Q11, no. (%)	12961 (93.88%)	8232 (91.97%)	4729 (97.4%)	5122 (89.86%)	3395 (97.75%)	2188 (95.8%)	1316 (98.5%)	723 (99.31%)	217 (98.19%)
Extremely negative	345 (2.66%)	161 (1.96%)	184 (3.89%)	82 (1.6%)	110 (3.24%)	50 (2.29%)	43 (3.27%)	51 (7.05%)	9 (4.15%)
Rather negative	836 (6.45%)	392 (4.76%)	444 (9.39%)	255 (4.98%)	280 (8.25%)	79 (3.61%)	112 (8.51%)	93 (12.86%)	17 (7.83%)
Neutral	2967 (22.89%)	1716 (20.85%)	1251 (26.45%)	1073 (20.95%)	1006 (29.63%)	391 (17.87%)	295 (22.42%)	161 (22.27%)	41 (18.89%)
Rather positive	5381 (41.52%)	3672 (44.61%)	1709 (36.14%)	2238 (43.69%)	1246 (36.7%)	976 (44.61%)	594 (45.14%)	232 (32.09%)	95 (43.78%)
Extremely positive	3432 (26.48%)	2291 (27.83%)	1141 (24.13%)	1474 (28.78%)	753 (22.18%)	692 (31.63%)	272 (20.67%)	186 (25.73%)	55 (25.35%)
Q12, no. (%)	12563 (91%)	7931 (88.6%)	4632 (95.41%)	4887 (84.78%)	3331 (95.91%)	2123 (92.95%)	1294 (96.86%)	721 (99.04%)	207 (93.67%)
A high degree of accuracy, the decision path is clearly comprehensible (explainable AI).	8816 (70.17%)	5599 (70.6%)	3217 (69.45%)	3304 (67.61%)	2091 (62.77%)	1704 (80.26%)	1045 (80.76%)	520 (72.12%)	152 (73.43%)
A higher accuracy, the decision path however, is not comprehensible.	3747 (29.83%)	2332 (29.4%)	1415 (30.55%)	1583 (32.39%)	1240 (37.23%)	419 (19.74%)	249 (19.24%)	201 (27.88%)	55 (26.57%)
Q13, no. (%)	12268 (88.86%)	7671 (85.7%)	4597 (94.69%)	4680 (81.19%)	3301 (95.05%)	2086 (91.33%)	1285 (96.18%)	710 (97.53%)	206 (93.21%)
The AI misses almost no diagnosis, but often gives a false alarm.	5701 (46.47%)	3725 (48.56%)	1976 (42.98%)	2224 (47.52%)	1323 (40.08%)	1025 (49.14%)	673 (52.37%)	336 (47.32%)	120 (58.25%)

Table 2. Absolute survey results and regional breakdowns for each item.

	Total (N=13806)	Global North (N=8951)	Global South (N=4855)	Europe (N=5764)	Asia (N=3473)	North America (N=2284)	South America (N=1336)	Africa (N=728)	Oceania (N=221)
The AI almost never gives a false alarm, but sometimes misses a diagnosis.	4452 (36.29%)	2663 (34.72%)	1789 (38.92%)	1668 (35.64%)	1296 (39.26%)	732 (35.09%)	456 (35.49%)	243 (34.23%)	57 (27.67%)
The AI gives a false alarm about as often as it misses a diagnosis.	2115 (17.24%)	1283 (16.73%)	832 (18.1%)	788 (16.84%)	682 (20.66%)	329 (15.77%)	156 (12.14%)	131 (18.45%)	29 (14.08%)
Q14, no. (%)	12652 (91.64%)	8089 (90.37%)	4563 (93.99%)	5012 (86.95%)	3305 (95.16%)	2157 (94.44%)	1244 (93.11%)	720 (98.9%)	214 (96.83%)
Physicians make the diagnosis alone.	829 (6.55%)	570 (7.05%)	259 (5.68%)	345 (6.88%)	198 (5.99%)	111 (5.15%)	113 (9.08%)	51 (7.08%)	11 (5.14%)
AI and physicians make the diagnosis together. Doctors make the final decision.	9222 (72.89%)	6092 (75.31%)	3130 (68.6%)	3853 (76.88%)	2212 (66.93%)	1594 (73.9%)	896 (72.03%)	496 (68.89%)	171 (79.91%)
AI and physicians make the diagnosis together. Both have equal authority.	1722 (13.61%)	1063 (13.14%)	659 (14.44%)	574 (11.45%)	563 (17.03%)	298 (13.82%)	152 (12.22%)	114 (15.83%)	21 (9.81%)
AI and physicians make the diagnosis together. The AI makes the final decision.	317 (2.51%)	153 (1.89%)	164 (3.59%)	111 (2.21%)	98 (2.97%)	30 (1.39%)	40 (3.22%)	34 (4.72%)	4 (1.87%)
AI makes the diagnosis alone.	562 (4.44%)	211 (2.61%)	351 (7.69%)	129 (2.57%)	234 (7.08%)	124 (5.75%)	43 (3.46%)	25 (3.47%)	7 (3.27%)
Q15, no. (%)	12652 (91.64%)	8077 (90.24%)	4575 (94.23%)	4992 (86.61%)	3244 (93.41%)	2167 (94.88%)	1312 (98.2%)	723 (99.31%)	214 (96.83%)
Extremely negative	322 (2.55%)	138 (1.71%)	184 (4.02%)	69 (1.38%)	93 (2.87%)	39 (1.8%)	38 (2.9%)	76 (10.51%)	7 (3.27%)
Rather negative	895 (7.07%)	419 (5.19%)	476 (10.4%)	274 (5.49%)	338 (10.42%)	89 (4.11%)	103 (7.85%)	75 (10.37%)	16 (7.48%)
Neutral	3594 (28.41%)	2381 (29.48%)	1213 (26.51%)	1555 (31.15%)	890 (27.44%)	502 (23.17%)	434 (33.08%)	159 (21.99%)	54 (25.23%)

Table 2. Absolute survey results and regional breakdowns for each item.

	Total (N=13806)	Global North (N=8951)	Global South (N=4855)	Europe (N=5764)	Asia (N=3473)	North America (N=2284)	South America (N=1336)	Africa (N=728)	Oceania (N=221)
Rather positive	5228 (41.32%)	3617 (44.78%)	1611 (35.21%)	2184 (43.75%)	1219 (37.58%)	990 (45.69%)	494 (37.65%)	242 (33.47%)	99 (46.26%)
Extremely positive	2613 (20.65%)	1522 (18.84%)	1091 (23.85%)	910 (18.23%)	704 (21.7%)	547 (25.24%)	243 (18.52%)	171 (23.65%)	38 (17.76%)
Q16, no. (%)	12497 (90.52%)	7947 (88.78%)	4523 (93.16%)	4905 (85.1%)	3214 (92.54%)	2150 (94.13%)	1298 (97.16%)	715 (98.21%)	215 (97.29%)
Always prefer facilities without AI.	775 (6.2%)	426 (5.36%)	349 (7.72%)	299 (6.1%)	213 (6.63%)	78 (3.63%)	130 (10.02%)	38 (5.31%)	17 (7.91%)
Tend to prefer facilities without AI.	2800 (22.41%)	1855 (23.34%)	945 (20.89%)	1183 (24.12%)	645 (20.07%)	426 (19.81%)	355 (27.35%)	126 (17.62%)	65 (30.23%)
Rather prefer facilities with AI.	7022 (56.19%)	4750 (59.77%)	2272 (50.23%)	2841 (57.92%)	1808 (56.25%)	1287 (59.86%)	656 (50.54%)	314 (43.92%)	116 (53.95%)
Always prefer facilities with AI.	1900 (15.2%)	943 (11.87%)	957 (21.16%)	582 (11.87%)	548 (17.05%)	359 (16.7%)	157 (12.1%)	237 (33.15%)	17 (7.91%)
Q17, no. (%)	12668 (91.76%)	8104 (90.54%)	4564 (94.01%)	5019 (87.07%)	3239 (93.26%)	2161 (94.61%)	1311 (98.13%)	722 (99.18%)	216 (97.74)
Very worried	2324 (18.35%)	1497 (18.47%)	827 (18.12%)	718 (14.31%)	441 (13.62%)	703 (32.53%)	267 (20.37%)	152 (21.05%)	43 (19.91%)
Somewhat concerned	4413 (34.84%)	2830 (34.92%)	1583 (34.68%)	1673 (33.33%)	1233 (38.07%)	727 (33.64%)	441 (33.64%)	252 (34.9%)	87 (40.28%)
Neutral	3595 (28.38%)	2220 (27.39%)	1375 (30.13%)	1513 (30.15%)	1008 (31.12%)	453 (20.96%)	350 (26.7%)	213 (29.5%)	58 (26.85%)
Rather unconcerned	1627 (12.84%)	1115 (13.76%)	512 (11.22%)	775 (15.44%)	394 (12.16%)	219 (10.13%)	151 (11.52%)	67 (9.28%)	21 (9.72%)
Unconcerned	709 (5.6%)	442 (5.45%)	267 (5.85%)	340 (6.77%)	163 (5.03%)	59 (2.73%)	102 (7.78%)	38 (5.26%)	7 (3.24%)
Q18, no. (%)	12669 (91.76%)	8109 (90.59%)	4560 (93.92%)	5025 (87.18%)	3237 (93.2%)	2160 (94.59%)	1312 (98.2%)	719 (98.76%)	216 (97.74%)
Very worried	3123 (24.65%)	2150 (26.51%)	973 (21.34%)	1206 (24%)	516 (15.94%)	786 (36.39%)	385 (29.34%)	177 (24.62%)	53 (24.54%)
Somewhat concerned	4700 (37.1%)	3174 (39.14%)	1526 (33.46%)	2023 (40.26%)	1265 (39.08%)	698 (32.31%)	375 (28.58%)	241 (33.52%)	98 (45.37%)

Table 2. Absolute survey results and regional breakdowns for each item.

	Total (N=13806)	Global North (N=8951)	Global South (N=4855)	Europe (N=5764)	Asia (N=3473)	North America (N=2284)	South America (N=1336)	Africa (N=728)	Oceania (N=221)
Neutral	2958 (23.35%)	1699 (20.95%)	1259 (27.61%)	1044 (20.78%)	882 (27.25%)	467 (21.62%)	338 (25.76%)	183 (25.45%)	44 (20.37%)
Rather unconcerned	1399 (11.04%)	862 (10.63%)	537 (11.78%)	593 (11.8%)	403 (12.45%)	178 (8.24%)	133 (10.14%)	76 (10.57%)	16 (7.41%)
Unconcerned	489 (3.86%)	224 (2.76%)	265 (5.81%)	159 (3.16%)	171 (5.28%)	31 (1.44%)	81 (6.17%)	42 (5.84%)	5 (2.31%)
Q19, no. (%)	12773 (92.52%)	8105 (90.55%)	4668 (96.15%)	5025 (87.18%)	3341 (96.20%)	2158 (94.48%)	1311 (98.13%)	722 (99.18%)	216 (97.74%)
Very worried	3868 (30.28%)	2724 (33.61%)	1144 (24.51%)	1580 (31.44%)	593 (17.75%)	918 (42.54%)	466 (35.55%)	230 (31.86%)	81 (37.5%)
Somewhat concerned	4018 (31.46%)	2743 (33.84%)	1275 (27.31%)	1717 (34.17%)	1102 (32.98%)	647 (29.98%)	293 (22.35%)	187 (25.9%)	72 (33.33%)
Neutral	2595 (20.32%)	1409 (17.38%)	1186 (25.41%)	841 (16.74%)	867 (25.95%)	375 (17.38%)	334 (25.48%)	143 (19.81%)	35 (16.2%)
Rather unconcerned	1571 (12.3%)	910 (11.23%)	661 (14.16%)	647 (12.88%)	501 (15%)	180 (8.34%)	131 (9.99%)	89 (12.33%)	23 (10.65%)
Unconcerned	721 (5.64%)	319 (3.94%)	402 (8.61%)	240 (4.78%)	278 (8.32%)	38 (1.76%)	87 (6.64%)	73 (10.11%)	5 (2.31%)
Q20, no. (%)	12751 (92.36%)	8091 (90.39%)	4660 (95.98%)	5009 (86.9%)	3334 (96%)	2159 (94.53%)	1310 (98.05%)	723 (99.31%)	216 (97.74%)
Very worried	3330 (26.12%)	2151 (26.59%)	1179 (25.3%)	1093 (21.82%)	676 (20.28%)	845 (39.14%)	421 (32.14%)	245 (33.89%)	50 (23.15%)
Somewhat concerned	3989 (31.28%)	2439 (30.14%)	1550 (33.26%)	1408 (28.11%)	1241 (37.22%)	688 (31.87%)	362 (27.63%)	215 (29.74%)	75 (34.72%)
Neutral	3356 (26.32%)	2205 (27.25%)	1151 (24.7%)	1518 (30.31%)	872 (26.15%)	444 (20.57%)	327 (24.96%)	132 (18.26%)	63 (29.17%)
Rather unconcerned	1365 (10.71%)	885 (10.94%)	480 (10.3%)	683 (13.64%)	359 (10.77%)	128 (5.93%)	127 (9.69%)	51 (7.05%)	17 (7.87%)
Unconcerned	711 (5.58%)	411 (5.08%)	300 (6.44%)	307 (6.13%)	186 (5.58%)	54 (2.5%)	73 (5.57%)	80 (11.07%)	11 (5.09%)

Abbreviations: Q1, What are your general views on the use of artificial intelligence (AI) in medicine?; Q2, Artificial intelligence (AI) should be increasingly used in the healthcare sector.; Q3, How much confidence do you have that AI can improve healthcare?; Q4, How much do you trust an AI to provide reliable information about your health?; Q5, How much do you trust an AI to provide accurate information about your diagnosis?; Q6, How much do you trust an AI to provide accurate information about your response to therapy?; Q7, Which of the following statements about a potential application of AI in medicine do you most likely agree with?; Q8, I would trust a highly accurate AI to make a vital decision for me.; Q9, How would you rate it if a certified AI software analyzes X-ray images?; Q10, How would you rate it if a certified AI software diagnoses cancer?; Q11, How would you rate it if a certified AI software would be available to doctors as a second opinion?; Q12/Q13, Suppose an AI makes a diagnosis. What would you prefer?; Q14, Suppose an AI has about the same accuracy as doctors. Which situation for a diagnosis would you prefer?; Q15, What do you think of healthcare facilities (clinics, practices) using AI software to aid in diagnosis?; Q16, Would you prefer to visit healthcare facilities that use AI software? Q17, How concerned are you about AI compromising

the protection of your personal data?; Q18, How concerned are you that the use of AI will reduce the contact between physicians and patients?; Q19, How concerned are you that AI could replace human doctors in the future?; Q20, How concerned are you that the use of AI will lead to higher healthcare costs?.

Supplementary Material Captions

eTable 1. Baseline characteristics of excluded patients.

eTable 2. Overview of participating institutions, departments, and patients.

eTable 3. Adjusted odds ratios for self-reported gender from regression analyses.

eTable 4. Adjusted odds ratios for self-reported health status from regression analyses.

eTable 5. Adjusted odds ratios for self-reported AI knowledge from regression analyses.

eTable 6. Adjusted odds ratios for age and number of technical devices used weekly from regression analyses.

eTable 7. Adjusted odds ratios for highest educational level from regression analyses.

eTable 8. Absolute survey results for each item stratified by gender.

eTable 9. Absolute survey results for each item stratified by self-reported health status.

eTable 10. Absolute survey results for each item stratified by self-reported AI knowledge.




eTable 11. Absolute survey results for each item stratified by median age and median number of technical devices used weekly.

eTable 12. Absolute survey results for each item stratified by highest educational level.


eTable 13. STROBE statement.

eTable 14. Institutional review board approval information.


eTable 15. Baseline characteristics of the pilot study group.

A**B****C****D****E****F**


Q1: What are your general views on the use of artificial intelligence (AI) in medicine?




Q2: Artificial intelligence (AI) should be increasingly used in the healthcare sector.




Q3: How much confidence do you have that AI can improve healthcare?




Q4: How much do you trust an AI to provide reliable information about your health?




Q5: How much do you trust an AI to provide accurate information about your diagnosis?




Q6: How much do you trust an AI to provide accurate information about your response to therapy?




Q7: Which of the following statements about a potential application of AI in medicine do you most likely agree with?




Q8: I would trust a highly accurate AI to make a vital decision for me.




Q9: How would you rate it if a certified AI software analyzes X-ray images?




Q10: How would you rate it if a certified AI software diagnoses cancer?




Q11: How would you rate it if a certified AI software would be available to doctors as a second opinion?




Q12: Suppose an AI makes a diagnosis. What would you prefer?




Q13: Suppose an AI makes a diagnosis. What would you prefer?




Q14: Suppose an AI has about the same accuracy as doctors. Which situation for a diagnosis would you prefer?




Q15: What do you think of healthcare facilities (clinics, practices) using AI software to aid in diagnosis?




Q16: Would you prefer to visit healthcare facilities that use AI software?




Q17: How concerned are you about AI compromising the protection of your personal data?



Q18: How concerned are you that the use of AI will reduce the contact between physicians and patients?



Q19: How concerned are you that AI could replace doctors in the future?



Q20: How concerned are you that the use of AI will lead to higher healthcare costs?

